Azapolycyclic compound, preparation method therefor and use thereof
Patent Information
- Application Number
- PCT/CN2026/083288
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-03-09
- Filing Date
- 2026-03-13
- Publication Date
- 2026-09-17
Smart Images

Figure CN2026083288_17092026_PF_FP_ABST
Abstract
Description
A nitrogen-containing polycyclic compound, its preparation method and application
[0001] This application claims priority to Chinese patent applications filed on March 13, 2025: 2025102989971; April 14, 2025: 202510462981X; May 30, 2025: 2025107226702; September 19, 2025: 2025; December 31, 2025: 2025: 2025120555542; and March 9, 2026: 2026102825980. The full text of the aforementioned Chinese patent applications is incorporated herein by reference. Technical Field
[0002] This invention relates to a nitrogen-containing heterocyclic compound, its preparation method, and its applications. Background Technology
[0003] TNFα (tumor necrosis factor) is a cytokine with multiple biological effects discovered in the 1970s and is the first typical member of the TNF superfamily (TNFSF) of ligands. TNFα is a type II transmembrane protein that can be secreted in a soluble form after being cleaved by metalloproteinases. In its native state, TNFα exists as a trimer. Only when the trimer form of TNFα binds to the extracellular region of TNFR1 can it induce the trimerization of TNFR1, thereby effectively activating downstream pathways. TNFα is secreted by monocytes, macrothiazides, and T cells activated by interaction with TNFRs. By binding to specific receptors on the cell membrane, it activates three signaling pathways: caspase, JNK, and the transcription factor NF-κB, thereby inducing multiple different biological processes and ultimately achieving its biological functions of regulating cell growth and apoptosis, tumorigenesis, immunity, inflammation, and stress responses.
[0004] Currently, many TNFα modulators have been developed and are commercially available. Clinically proven, inhibiting the binding of TNFα to TNFR1 and TNFR2 is used to treat or prevent many TNFα-mediated human diseases, including inflammatory and autoimmune diseases, and neurodegenerative diseases. All currently approved products are large molecules and work by inhibiting the binding of human TNFα to its receptors. Examples include adalimumab, golimumab, certoizumab pegol, infliximab, and etanercept.
[0005] Given the limited efficacy and certain clinical side effects of clinical antibody drugs, there is a need to develop small molecule inhibitors that can regulate TNFα signaling.
[0006] This invention relates to a new class of heterocyclic compounds that serve as effective inhibitors of TNFα activity. These compounds exhibit highly efficient TNFα inhibition and good drug-like properties. Summary of the Invention
[0007] This invention provides compounds of formula (I-1), their stereoisomers, or pharmaceutically acceptable salts thereof.
[0008] in,
[0009] T x Selected from N, CH and C;
[0010] T y Selected from N, CH and C;
[0011] T is selected from N and C;
[0012] When T is selected from N Selected from
[0013] When T is selected from C Selected from
[0014] T4 is selected from N and C(R2);
[0015] T5 is selected from N and C(R3);
[0016] T6 is selected from N and C(R4);
[0017] T7 is selected from N and C(R5);
[0018] And at most two of T4, T5, T6, and T7 can be selected from N simultaneously;
[0019] T8 is selected from N and CH;
[0020] T9 is selected from N and C (R9);
[0021] Furthermore, at least one of T8 and T9 is selected from N;
[0022] X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )2C(R b )2-、-C(R b)=C(R b )- and -C(R b )2-N(R a )-;
[0023] Alternatively, when X1 is selected from -C(R) b )2-N(R a When )-, where R a With one of the R b They connect together to form a 4-6 membered heterocyclic alkyl group;
[0024] X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-;
[0025] Z is selected from -C(R) a )2- and -C(R b )2-;
[0026] L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups;
[0027] Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0028] Ring B is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl, the C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl groups may be optionally replaced by R6, R7, or R8;
[0029] Ring C is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0030] Selected from
[0031] when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3- 10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R;
[0032] when Selected from R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10-membered heterocyclic alkenyl, wherein R1 is optionally substituted with one or more R;
[0033] R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R;
[0034] Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0035] Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0036] Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0037] R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1- 6-alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1- 6-alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R;
[0038] R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0039] R 10 Selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1- 6-alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0040] Alternatively, R8 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0041] Or, R7 and R 10 Connected together, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0042] Or, R 10 Connected together with R2, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0043] R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's;
[0044] R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's;
[0045] Alternatively, R9 with the substituent R on X2 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R;
[0046] Or, two Rs a Connected together, forming a C 4-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 4-7 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0047] Alternatively, when T is selected from N, R5 and the substituent R on X2 b They are linked together to form a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by one or more R;
[0048] Alternatively, when T is selected from C, R5 is linked with X2 to form a 6-membered heteroaryl group, which may be optionally replaced by one or more R groups;
[0049] Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0050] Or, R 10 With the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0051] R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution;
[0052] n is selected from 0, 1, 2 or 3.
[0053] In some embodiments of the present invention, the compound represented by formula (I-1), its stereoisomer, or a pharmaceutically acceptable salt thereof is selected from the compound represented by formula (I) or formula (II), its stereoisomer, or a pharmaceutically acceptable salt thereof.
[0054] in,
[0055] T xSelected from N, CH and C;
[0056] T y Selected from N, CH and C;
[0057] T is selected from N and C;
[0058] When T is selected from N Selected from
[0059] When T is selected from C Selected from
[0060] T4 is selected from N and C(R2);
[0061] T5 is selected from N and C(R3);
[0062] T6 is selected from N and C(R4);
[0063] T7 is selected from N and C(R5);
[0064] And at most two of T4, T5, T6, and T7 can be selected from N simultaneously;
[0065] X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )=C(R b )--C(R b )2C(R b )2- and -C(R b )2-N(R a -; or, when X1 is selected from -C(R) b )2-N(R a When )-, where R a With one of the R b They connect together to form a 4-6 membered heterocyclic alkyl group;
[0066] X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-;
[0067] Z is selected from -C(R) a )2- and -C(R b )2-;
[0068] L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups;
[0069] Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0070] Ring B is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl, the C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl groups may be optionally replaced by R6, R7, or R8;
[0071] Ring C is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0072] Selected from
[0073] when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3- 10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R;
[0074] when Selected from R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10-membered heterocyclic alkenyl, wherein R1 is optionally substituted with one or more R;
[0075] R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R;
[0076] Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0077] Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0078] Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0079] R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1- 6-alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1- 6-alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R;
[0080] R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0081] R 10 Selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1- 6-alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0082] Alternatively, R8 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0083] Or, R7 and R 10 Connected together, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0084] Or, R 10 Connected together with R2, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0085] R a Selected from H, C1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's;
[0086] R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's;
[0087] Alternatively, R9 with the substituent R on X2 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R;
[0088] Or, two Rs a Connected together, forming a C 4-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 4-7 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0089] Alternatively, when T is selected from N, R5 and the substituent R on X2 b They are linked together to form a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by one or more R;
[0090] Alternatively, when T is selected from C, R5 is linked with X2 to form a 6-membered heteroaryl group, which may be optionally replaced by one or more R groups;
[0091] Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0092] Or, R 10 With the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0093] R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution;
[0094] n is selected from 0, 1, 2 or 3.
[0095] In some embodiments of the present invention, structural units Selected from
[0096] In some embodiments of the present invention, the compound represented by formula (I) or formula (II), its stereoisomer, or a pharmaceutically acceptable salt thereof, is selected from the compound represented by formula (IA), formula (IB), formula (II-A), or formula (II-B), its stereoisomer, or a pharmaceutically acceptable salt thereof.
[0097] in,
[0098] T1 is selected from N and C(R6);
[0099] T2 is selected from N and C (R7);
[0100] T3 is selected from N and C(R8);
[0101] T4 is selected from N and C(R2);
[0102] T5 is selected from N and C(R3);
[0103] T6 is selected from N and C(R4);
[0104] T7 is selected from N and C(R5);
[0105] And at most two of T4, T5, T6, and T7 can be selected from N simultaneously;
[0106] X1 is selected from empty, -O-, -S-, -N(R)a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )=C(R b )- and -C(R b )2C(R b )2-;
[0107] X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-;
[0108] Z is selected from -C(R) a )2- and -C(R b )2-;
[0109] L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups;
[0110] Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0111] Selected from
[0112] when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3- 10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R;
[0113] when Selected from When R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10-membered heterocyclic alkenyl, wherein R1 is optionally substituted with one or more R;
[0114] R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R;
[0115] Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0116] Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0117] Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0118] R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1- 6-alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1- 6-alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R;
[0119] R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0120] Alternatively, R6 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0121] R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's;
[0122] R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's;
[0123] Alternatively, R9 and the substituent R on X1 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R;
[0124] Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0125] Alternatively, the two substituents R on Z a Connected together, forming a C 3-10 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0126] R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution;
[0127] n is selected from 0, 1, 2 or 3.
[0128] In some embodiments of the present invention, the compound represented by formula (I) or formula (II), its stereoisomers, or pharmaceutically acceptable salts thereof, is selected from the compound represented by formula (I-A1), formula (I-A2), formula (II-A1), or formula (II-A2), or its pharmaceutically acceptable salts, their stereoisomers, or pharmaceutically acceptable salts thereof.
[0129] in,
[0130] T1 is selected from N and C(R6);
[0131] T2 is selected from N and C (R7);
[0132] T3 is selected from N and C(R8);
[0133] T4 is selected from N and C(R2);
[0134] T5 is selected from N and C(R3);
[0135] T6 is selected from N and C(R4);
[0136] T7 is selected from N and C(R5);
[0137] And at most two of T4, T5, T6, and T7 can be selected from N simultaneously;
[0138] X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )=C(R b )- and -C(R b )2C(R b )2-;
[0139] X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-;
[0140] Z is selected from -C(R) a )2- and -C(R b )2-;
[0141] L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups;
[0142] Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0143] Selected from
[0144] when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3- 10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R;
[0145] when Selected from When R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2- and 5-10-membered heterocyclic alkenyl-CH2-, wherein R1 is optionally substituted with one or more R;
[0146] R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R;
[0147] Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0148] Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0149] Alternatively, R4 and R5 can be connected together to form a C.5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0150] R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1- 6-alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1- 6-alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R;
[0151] R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0152] Alternatively, R6 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0153] R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's;
[0154] R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's;
[0155] Alternatively, R9 and the substituent R on X1 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R;
[0156] Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0157] Alternatively, the two substituents R on Z a Connected together, forming a C 3-10 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R;
[0158] R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1-6 Alkyl)3, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5- 10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution;
[0159] n is selected from 0, 1, 2 or 3.
[0160] In some embodiments of the present invention, the compound represented by formula (I) or formula (II), its stereoisomers, or pharmaceutically acceptable salts thereof, is selected from the compound represented by formula (III-A1) or formula (III-A2), its pharmaceutically acceptable salts, its stereoisomers, or pharmaceutically acceptable salts thereof.
[0161] q is selected from 0, 1, 2 or 3.
[0162] In some embodiments of the present invention, R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1- 3-alkyl)3, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-6 Cycloalkyl-C(=O)-, 3-6 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10-membered heterocyclic alkenyl-C(=O)-, phenyl-C(=O)-, and 5-6-membered heteroaryl-C(=O)-, wherein R is optionally converted by one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino or (C 1-3 Alkane)2-amino substitution.
[0163] In some embodiments of the present invention, R is selected from D, F, Cl, Br, I, OH, NH2, CN, Si(CH3)3, methyl, ethyl, propyl, isopropyl, CD3,
[0164] In some embodiments of the present invention, when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)(=NH)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 1- 3alkyl-NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-10 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3- 10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R;
[0165] when Selected from When R1 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, C 5-6 Cycloalkenyl, 5-6 membered heterocyclic alkenyl, C 3-6 Cycloalkyl-CH2-, 4-6 membered heterocyclic alkyl-CH2-, C 5-6 Cycloalkenyl-CH2- and 5-6 membered heterocyclic alkenyl-CH2-.
[0166] In some embodiments of the present invention, when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Methyl, ethyl, isopropyl, CD3, CF3
[0167] when Selected from When, R1 is selected
[0168] In some embodiments of the present invention, T4 is selected from C(R2), T5 is selected from C(R3), T6 is selected from C(R4), and T7 is selected from C(R5).
[0169] In some embodiments of the present invention, T4 is selected from C(R2), T5 is selected from N, T6 is selected from C(R4), and T7 is selected from C(R5).
[0170] In some embodiments of the present invention, T4 is selected from C(R2), T5 is selected from C(R3), T6 is selected from N, and T7 is selected from C(R5).
[0171] In some embodiments of the present invention, T4 is selected from C(R2), T5 is selected from C(R3), T6 is selected from C(R4), and T7 is selected from N.
[0172] In some embodiments of the present invention, T4 is selected from N, T5 is selected from C(R3), T6 is selected from N, and T7 is selected from C(R5).
[0173] In some embodiments of the present invention, T4 is selected from C(R2), T5 is selected from N, T6 is selected from C(R4), and T7 is selected from N.
[0174] In some embodiments of the present invention, R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C1-3 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10-membered heterocyclic alkenyl-O-, phenyl-O-, 5-6-membered heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10-membered heterocyclic alkenyl-S-, phenyl-S-, 5-6-membered heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, phenyl-NH-, 5-6 membered heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10-membered heterocyclic alkenyl-CH2-, phenyl-CH2-, 5-6-membered heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more Rs.
[0175] In some embodiments of the present invention, R2 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5- 10 Cycloalkenyl-O-, 5-10-membered heterocyclic alkenyl-O-, phenyl-O-, 5-6-membered heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10-membered heterocyclic alkenyl-S-, phenyl-S-, 5-6-membered heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, phenyl-NH-, 5-6 membered heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10-membered heterocyclic alkenyl-CH2-, phenyl-CH2-, 5-6-membered heteroaryl-CH2-, wherein R2 is optionally substituted with one or more Rs.
[0176] In some embodiments of the present invention, R3 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5- 10 Cycloalkenyl-O-, 5-10-membered heterocyclic alkenyl-O-, phenyl-O-, 5-6-membered heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 quinone / heterocyclic alkenyl-S-, phenyl-S-, 5-6 quinone heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, phenyl-NH-, 5-6 membered heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10-membered heterocyclic alkenyl-CH2-, phenyl-CH2-, 5-6-membered heteroaryl-CH2-, wherein R3 is optionally substituted with one or more Rs.
[0177] In some embodiments of the present invention, R4 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5- 10 Cycloalkenyl-O-, 5-10-membered heterocyclic alkenyl-O-, phenyl-O-, 5-6-membered heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10-membered heterocyclic alkenyl-S-, phenyl-S-, 5-6-membered heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, phenyl-NH-, 5-6 membered heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10-membered heterocyclic alkenyl-CH2-, phenyl-CH2-, 5-6-membered heteroaryl-CH2-, wherein R4 is optionally substituted with one or more Rs.
[0178] In some embodiments of the present invention, R5 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5- 10 Cycloalkenyl-O-, 5-10-membered heterocyclic alkenyl-O-, phenyl-O-, 5-6-membered heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10-membered heterocyclic alkenyl-S-, phenyl-S-, 5-6-membered heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, phenyl-NH-, 5-6 membered heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10-membered heterocyclic alkenyl-CH2-, phenyl-CH2-, 5-6-membered heteroaryl-CH2-, wherein R5 is optionally substituted with one or more Rs.
[0179] In some embodiments of the present invention, R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, ...
[0180] In some embodiments of the present invention, R2 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2,
[0181] In some embodiments of the present invention, R3 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2,
[0182] In some embodiments of the present invention, R3 is selected from H, D, F, and Cl.
[0183] In some embodiments of the present invention, R4 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2,
[0184] In some embodiments of the present invention, R4 is selected from H, D, F, and Cl.
[0185] In some embodiments of the present invention, R5 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2,
[0186] In some embodiments of the present invention, R5 is selected from H, D, F, and Cl.
[0187] In some embodiments of the present invention, R2 is derived from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, R3, R4, and R5 are each independently selected from H and F.
[0188] In some embodiments of the present invention, R6 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 Aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6 is optionally substituted by one or more Rs.
[0189] In some embodiments of the present invention, R6 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, wherein the alkanoylamino group is optionally substituted with one or more R groups.
[0190] In some embodiments of the present invention, R6 is selected from H, D, F, Cl, Br, I, OH, NH2 and CN.
[0191] In some embodiments of the present invention, R6 is selected from H.
[0192] In some embodiments of the present invention, R6 is selected from D.
[0193] In some embodiments of the present invention, R6 is selected from F.
[0194] In some embodiments of the present invention, R7 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 Aryl-CH2- or 5-10 heteroaryl-CH2-, wherein R7 is optionally substituted by one or more Rs.
[0195] In some embodiments of the present invention, R7 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, wherein the alkanoylamino group is optionally substituted with one or more R groups.
[0196] In some embodiments of the present invention, R7 is selected from H, D, F, Cl, Br, I, OH, NH2 and CN.
[0197] In some embodiments of the present invention, R7 is selected from H.
[0198] In some embodiments of the present invention, R7 is selected from D.
[0199] In some embodiments of the present invention, R7 is selected from F.
[0200] In some embodiments of the present invention, R8 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 Aryl-CH2-, 5-10 heteroaryl-CH2-, wherein the R8 is optionally substituted by one or more Rs.
[0201] In some embodiments of the present invention, R8 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, wherein the alkanoylamino group is optionally substituted with one or more R groups.
[0202] In some embodiments of the present invention, R8 is selected from H, D, F, Cl, Br, I, OH, NH2 and CN.
[0203] In some embodiments of the present invention, R8 is selected from H.
[0204] In some embodiments of the present invention, R8 is selected from D.
[0205] In some embodiments of the present invention, R8 is selected from F.
[0206] In some embodiments of the present invention, T1 is selected from C(R6).
[0207] In some embodiments of the present invention, T1 is selected from N.
[0208] In some embodiments of the present invention, T2 is selected from C(R7).
[0209] In some embodiments of the present invention, T2 is selected from N.
[0210] In some embodiments of the present invention, T3 is selected from C(R8).
[0211] In some embodiments of the present invention, T3 is selected from N.
[0212] In some embodiments of the present invention, T1 is selected from C(R6), T2 is selected from C(R7), and T3 is selected from C(R8).
[0213] In some embodiments of the present invention, T1 is selected from N, T2 is selected from C(R7), and T3 is selected from C(R8).
[0214] In some embodiments of the present invention, T1 is selected from C(R6), T2 is selected from N, and T3 is selected from C(R8).
[0215] In some embodiments of the present invention, T1 is selected from C(R6), T2 is selected from C(R7), and T3 is selected from N.
[0216] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CH, and T3 is selected from CH.
[0217] In some embodiments of the present invention, T1 is selected from CD, T2 is selected from CH, and T3 is selected from CH.
[0218] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CD, and T3 is selected from CH.
[0219] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CH, and T3 is selected from CD.
[0220] In some embodiments of the present invention, T1 is selected from CD, T2 is selected from CD, and T3 is selected from CH.
[0221] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CD, and T3 is selected from CD.
[0222] In some embodiments of the present invention, T1 is selected from CD, T2 is selected from CH, and T3 is selected from CD.
[0223] In some embodiments of the present invention, T1 is selected from CD, T2 is selected from CD, and T3 is selected from CD.
[0224] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from CH, and T3 is selected from CH.
[0225] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CF, and T3 is selected from CH.
[0226] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CH, and T3 is selected from CF.
[0227] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from CF, and T3 is selected from CH.
[0228] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CF, and T3 is selected from CF.
[0229] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from CH, and T3 is selected from CF.
[0230] In some embodiments of the present invention, T1 is selected from N, T2 is selected from CH, and T3 is selected from CH.
[0231] In some embodiments of the present invention, T1 is selected from N, T2 is selected from CF, and T3 is selected from CH.
[0232] In some embodiments of the present invention, T1 is selected from N, T2 is selected from CH, and T3 is selected from CF.
[0233] In some embodiments of the present invention, T1 is selected from N, T2 is selected from CF, and T3 is selected from CF.
[0234] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from N, and T3 is selected from CH.
[0235] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from N, and T3 is selected from CH.
[0236] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from N, and T3 is selected from CF.
[0237] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from N, and T3 is selected from CF.
[0238] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CH, and T3 is selected from N.
[0239] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from CH, and T3 is selected from N.
[0240] In some embodiments of the present invention, T1 is selected from CH, T2 is selected from CF, and T3 is selected from N.
[0241] In some embodiments of the present invention, T1 is selected from CF, T2 is selected from CF, and T3 is selected from N.
[0242] In some embodiments of the present invention, the R a Selected from H, C 1-6 Deuterated alkyl, C 1-3 Alkyl and C 3-6 cycloalkyl, the C 1-3Alkyl groups may optionally be substituted with one or more R groups.
[0243] In some embodiments of the present invention, R8 is selected from H, D, and methyl.
[0244] In some embodiments of the present invention, R8 is selected from H.
[0245] In some embodiments of the present invention, R8 is selected from D.
[0246] In some embodiments of the present invention, R8 is selected from methyl.
[0247] In some embodiments of the present invention, R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, methyl, ethyl, isopropyl, cyclopropyl, CF3, CHF2, CH2F, CH2D, CD3,
[0248] In some embodiments of the present invention, R9 is selected from H, D, and methyl.
[0249] In some embodiments of the present invention, R9 is selected from H.
[0250] In some embodiments of the present invention, R9 is selected from D.
[0251] In some embodiments of the present invention, R9 is selected from methyl.
[0252] In some embodiments of the present invention, R8 is selected from H, and R9 is selected from H.
[0253] In some embodiments of the present invention, R8 is selected from D and R9 is selected from H.
[0254] In some embodiments of the present invention, R8 is selected from H and R9 is selected from D.
[0255] In some embodiments of the present invention, R8 is selected from H and R9 is selected from methyl.
[0256] In some embodiments of the present invention, R8 is selected from methyl and R9 is selected from H.
[0257] In some embodiments of the present invention, the R a It is selected from H, methyl, deuterated methyl, ethyl, propyl, isopropyl and cyclopropyl.
[0258] In some embodiments of the present invention, the R b Selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1- 3-alkyl, C 1-3 Alkoxy, C 1-3 alkylthio and C 1-3 Alkylamino, the Rb It can be replaced by one or more R's.
[0259] In some embodiments of the present invention, the R b Selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, methyl, ethyl, propyl and isopropyl.
[0260] In some embodiments of the present invention, X1 is selected from -N(R) a X2 is selected from -C(=O)-.
[0261] In some embodiments of the present invention, X1 is selected from -N(CH3)-, and X2 is selected from -C(=O)-. In some embodiments of the present invention, -X1-X2- is selected from -O-, -S-, -NH-, -N(CH3)-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -CH2-, -CH2CH2-, -C(=O)-O-, -C(=O)-NH-, -C(=O)-N(CH3)-, -C(=O)-CH2-, -S(=O)-O-, -S(=O)-NH-, -S( =O)-N(CH3)-, -S(=O)-CH2-, -S(=O)2-O-, -S(=O)2-NH-, -S(=O)2-N(CH3)-, -S(=O)2-CH2-, -O-CH2 -, -O-CH2CH2-, -S-CH2-, -S-CH2CH2-, -NH-CH2-, -NH-CH2CH2-, -N(CH3)-CH2-, -N(CH3)-CH2CH2-.
[0262] In some embodiments of the present invention, -X1-X2- is selected from...
[0263] In some embodiments of the present invention, -X1-X2- is selected from...
[0264] In some embodiments of the present invention, -X1-X2- is selected from...
[0265] In some embodiments of the present invention, Z is selected from -CH2-, -CHF-, -CF2-, -CH(CH3)- and -C(CH3)2-.
[0266] In some embodiments of the present invention, Z is selected from -CH2-.
[0267] In some embodiments of the present invention, the ring A is selected from furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazoleyl, oxazolyl, pyridyl, pyranoneyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, 2,3-dihydrofuran[3,2-b]pyridyl, 6,7-dihydro-5H-cyclopentan[b]pyridyl, 1H-pyrazolo[3,4-b]pyridyl, 3H-imidazo[4,5-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, 1,2,3,4-tetrahydro-1,8-naphthylpyridyl, 3,4-dihydro-2H-pyrido[3,2]pyridyl, 2,3,4-tetrahydro-1,8-naphthylpyridyl, 3,4-dihydro-2H-pyrido[3,2]pyridyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, 1,2,3,4-tetrahydro-1,8-naphthylpyridyl, 3,4-dihydro-2H-pyrido[3,2]pyridyl, 2,3 ... -b][1,4]oxazinyl, 3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazinyl, pyrazolo[1,5-a]pyrimidinyl, pyrrolo[2,1-f][1,2,4]triazinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, thiazo[5,4-b]pyridinyl, pyrrolo[1,2-a][1,3,5]triazinyl, 7H-pyrrolo[2,3-c]pyridazinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, 3,4-dihydro-2H-pyrano[3,2-b]pyridinyl, aziridine, pyrrolidinyl 2,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazolyl, spiro[3,3]heptyl, cyclopentyl, bicyclo[3,1,0]hexyl, 5a,6,7,7a-tetrahydrocyclobutane[4,5]furano[3,2-b]pyridyl, 5a,7,8,8a-tetrahydro-6H-cyclopentane[4,5]furano[3,2-b]pyridyl, 5a,6a-dihydro-6H-cyclopropane[4,5]furano[3,2-b]pyridyl, 5,5a,6,7,8,8a-hexahydropentene[1,2-b]pyridyl, 4b,5,5a,6-tetrahydrocyclopropane[3,4]cyclopentane[1,2-b]pyridyl, 5a,6,7,7a-tetrahydro-5H-cyclobutane[4, 5] Cyclopenta[1,2-b]pyridyl, 6a,7,8,8a-tetrahydro-6H-cyclobutane[4,5]pyrano[3,2-b]pyridyl, 2',3'-dihydrospiro[azacyclobutane-2,4'-pyrano[3,2-b]pyridyl]yl, 2',3'-dihydrospiro[aziridin-2,4'-pyrano[3,2-b]pyridyl]yl, 7,8-dihydro-6H-pyrano[2,3-b]pyrazinyl, 3,4-dihydro-2H-2,4-methanepyrano[3,2-b]pyridyl, 6,7-dihydro-5H-cyclopenta[b]pyrazinyl, 6,7-dihydro-5H-cyclopenta[c]pyridazinyl, phenyl, thiazolyl, isothiazolyl, isoxazolyl, 3-azabicyclo[4.2].[0] Octane-1(6),2,4-trienyl, 6,7-dihydro-5H-cyclopentan[c]pyridyl, 1,3-dihydrofuran[3,4-c]pyridyl, 2,3-dihydrofuran[2,3-c]pyridyl, nitropyridyl, nitropyridazinyl, nitropyrimidinyl, and nitropyrazinyl.
[0268] In some embodiments of the present invention,
[0269] Structural unit Selected from
[0270]
[0271]
[0272]
[0273] In some embodiments of the present invention, the ring L1 is selected from empty,
[0274] In some embodiments of the present invention, the structural unit Selected from
[0275]
[0276]
[0277]
[0278] In some embodiments of the present invention, R2 and R3 are connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5- The 7-membered cycloalkyl and 5-7-membered heterocycloalkyl may optionally be substituted with one or more R.
[0279] In some embodiments of the present invention, R2 and R3 are connected together to form
[0280] Alternatively, R3 and R4 can be connected together to form...
[0281] Alternatively, R4 and R5 can be connected together to form...
[0282] In some embodiments of the present invention, R2 and R3 are connected together to form
[0283] In some embodiments of the present invention, R3 and R4 are connected together to form
[0284] In some embodiments of the present invention, R4 and R5 are connected together to form
[0285] In some embodiments of the present invention, R6 and R1 are connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0286] Alternatively, R9 and the substituent R on X1 a They are linked together to form a 4-7 membered heterocyclic alkyl group, which may optionally be substituted with one or more R groups.
[0287] In some embodiments of the present invention, R6 and R1 are connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocyclic alkyl groups may optionally be substituted with one or more R groups.
[0288] In some embodiments of the present invention, the substituent R on R9 and X1 a They are linked together to form a 4-7 membered heterocyclic alkyl group, which may optionally be substituted with one or more R groups.
[0289] In some embodiments of the present invention, R6 is connected to R1 to form oxetyl, oxetylhexyl, azityl, azitylhexyl, oxetylheptyl or azitylheptyl, wherein the oxetyl, oxetyl, azityl, azityl, oxetylheptyl and azitylheptyl are optionally substituted by one or more R;
[0290] Alternatively, R9 and the substituent R on X1 a They are linked together to form azircyclobutyl, azircyclopentyl, azircyclohexyl, or azircycloheptyl, wherein the azircyclobutyl, azircyclopentyl, azircyclohexyl, and azircycloheptyl may optionally be substituted with one or more R.
[0291] In some embodiments of the present invention, R6 is connected to R1 to form oxacyclopentyl, oxacyclohexyl, azicyclopentyl, azicyclohexyl, oxacycloheptyl, or azicycloheptyl, wherein the oxacyclopentyl, oxacyclohexyl, azicyclopentyl, azicyclohexyl, oxacycloheptyl, and azicycloheptyl are optionally substituted by one or more R.
[0292] In some embodiments of the present invention, the substituent R on R9 and X1 a They are linked together to form azircyclobutyl, azircyclopentyl, azircyclohexyl, or azircycloheptyl, wherein the azircyclobutyl, azircyclopentyl, azircyclohexyl, and azircycloheptyl may optionally be substituted with one or more R.
[0293] In some embodiments of the present invention, R9 and the substituent R on Z are... a They connect together to form a cyclopropyl group.
[0294] In some embodiments of the present invention, the two substituents R on Z a They connect together to form a cyclopropyl group.
[0295] In some embodiments of the present invention, the compound represented by formula (I) or formula (II), its stereoisomers, or pharmaceutically acceptable salts thereof, is selected from the compound represented by formula (II-A3), formula (II-A4), or formula (II-A5), or its pharmaceutically acceptable salts, their stereoisomers, or pharmaceutically acceptable salts thereof.
[0296] in,
[0297] Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups;
[0298] Selected from
[0299] when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3- 10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R;
[0300] when Selected from When R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2- and 5-10-membered heterocyclic alkenyl-CH2-, wherein R1 is optionally substituted with one or more R;
[0301] R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R;
[0302] Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R;
[0303] R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1- 6-alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6-alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5- 10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R;
[0304] R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's;
[0305] R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1-6 Alkyl)3, C 1-6 Alkyl, C 1-6Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5- 10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution;
[0306] n is selected from 0, 1, 2 or 3.
[0307] In a preferred embodiment of the present invention, Selected from
[0308] In a preferred embodiment of the present invention, R aThe compound is selected from H, deuterated methyl, methyl, ethyl, propyl and isopropyl, wherein the deuterated methyl includes -CH2D, -CHD2, and -CD3;
[0309] In a preferred embodiment of the present invention, R2 and R3 are connected together to form
[0310] In a preferred embodiment of the present invention, R2, R3, R4, and R5 are each independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, ...
[0311] In a preferred embodiment of the present invention, R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Methyl, ethyl, isopropyl, The R1 may be optionally replaced by one or more Rs; in a preferred embodiment of the invention, R is selected from D, F, Cl, Br, I, OH, NH2, CN, Si(CH3)3, methyl, ethyl, propyl, isopropyl, CD3,
[0312] In one aspect of the invention, compounds of the following formula, their stereoisomers, or pharmaceutically acceptable salts thereof are also provided, selected from...
[0313] On the other hand, the present invention also provides pharmaceutical compositions comprising the above-described compounds, their stereoisomers, or pharmaceutically acceptable salts thereof.
[0314] On the other hand, the present invention also provides the use of the above-described compounds, their stereoisomers or pharmaceutically acceptable salts thereof, or the above-described pharmaceutical compositions in the preparation of TNFα inhibitor drugs.
[0315] On the other hand, the present invention also provides the use of the above-described compounds, their stereoisomers or pharmaceutically acceptable salts thereof, or the above-described pharmaceutical compositions in the preparation of medicaments for treating diseases related to TNFα.
[0316] In one embodiment of the present invention, the TNFα-related diseases are selected from anti-inflammatory disorders or autoimmune disorders, neurological disorders or neurodegenerative disorders, pain or nociceptive disorders, cardiovascular disorders, metabolic disorders, eye disorders or oncological disorders.
[0317] In one embodiment of the present invention, the TNFα-related diseases are selected from rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, psoriasis, Crohn's disease, ulcerative colitis, psoriasis, spondyloarthritis, plaque psoriasis, septic shock, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, uveitis, systemic lupus erythematosus, axial spondyloarthritis, polymyositis, pemphigus, multiple sclerosis, neuromyelitis optica, primary cholangitis, autoimmune hepatitis, lupus nephritis, pulmonary hemorrhage-nephritis syndrome, autoimmune oophoritis, or autoimmune orchitis.
[0318] definition
[0319] Unless otherwise stated, the following terms as used in this application shall have the following meanings. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.
[0320] The term “pharmaceutically acceptable” as used herein refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0321] The term "pharmaceutically acceptable salt" refers to a salt of the compounds of this invention, prepared by reacting a compound having specific substituents discovered in this invention with a relatively non-toxic acid or base. When the compounds of this invention contain relatively acidic functional groups, base addition salts can be obtained by contacting a neutral form of such compound with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amines, magnesium salts, or similar salts. When the compounds of this invention contain relatively basic functional groups, acid addition salts can be obtained by contacting a neutral form of such compound with a sufficient amount of acid in a solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, octanoic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; as well as salts of amino acids (such as arginine) and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain both basic and acidic functional groups, and thus can be converted into either a base or an acid addition salt.
[0322] The pharmaceutically acceptable salts of the present invention can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of a suitable base or acid in water or an organic solvent or a mixture thereof.
[0323] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their pharmaceutically acceptable salts, along with other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and its biological activity.
[0324] The term "substituted" refers to the substitution of one or more hydrogen atoms on a specific atom by a substituent, provided that the valence state of the specific atom is normal and the resulting compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are substituted; oxo substitution does not occur on aromatic groups.
[0325] The terms “optional” or “optionally” mean that the event or condition subsequently described may or may not occur, including both the occurrence and non-occurrence of said event or condition. For example, the ethyl group “optionally” being halogenated means that the ethyl group can be unsubstituted (CH2CH3), monosubstituted (e.g., CH2CH2F), polysubstituted (e.g., CHFCH2F, CH2CHF2, etc.), or fully substituted (CF2CF3). Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.
[0326] In this document, "one or more" refers to an integer from one to ten. For example, "one or more" means one, two, three, four, five, six, seven, eight, nine, or ten; or, "one or more" means one, two, three, four, five, or six; or, "one or more" means one, two, or three. Those skilled in the art will understand that for any group containing one or more substituents, no substitution or substitution pattern that is spatially impossible and / or cannot be synthesized is introduced.
[0327] C in this article m-n This means that the part has an integer number of carbon atoms within a given range. For example, "C 1-6 "" means that the group can have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms.
[0328] When any variable (e.g., R) appears more than once in the composition or structure of a compound, its definition is independent in each case. Therefore, for example, if a group is substituted by two Rs, each R has an independent option.
[0329] The term "alkyl" refers to a compound with the general formula C1. n H 2n+1 The alkyl group. This alkyl group can be straight-chain or branched. For example, the term "C 1-6 "Alkyl" refers to an alkyl group containing 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, neopentyl, hexyl, 2-methylpentyl, etc.). Similarly, the alkyl portion (i.e., alkyl) of alkoxy, alkylamino, dialkylamino, alkylsulfonyl, and alkylthio groups has the same definition as above.
[0330] The term "alkylene" refers to a compound with the general formula C1. n H 2n The divalent hydrocarbon group. For example, the term "C 1-6"Alkylene" refers to an alkylene containing 1 to 6 carbon atoms. Non-limiting examples of alkylene include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2- or -CH2CH(CH3)-), butylene (-CH2CH2CH2CH2-, -CH2CH(CH3)CH2- or -CH2CH2CH(CH3)-), pentylene, hexylene, etc.
[0331] The term "alkoxy" refers to alkyl-O-.
[0332] The term "alkylamino" refers to alkyl-NH-.
[0333] The term "alkylthio" refers to alkyl-S-.
[0334] The term "cycloalkyl" refers to a fully saturated carbon ring that can exist as a monocyclic, fused, bridged, or spirocyclic ring. Unless otherwise indicated, the carbon ring is typically a 3- to 10-membered ring; preferably a 3- to 6-membered ring. Non-limiting examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl (bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, decahydronaphthyl, etc.
[0335] The term "heterocyclic alkyl" refers to a fully saturated cyclic group that may exist as a monocyclic, bridged, or spirocyclic ring. Unless otherwise indicated, the heterocycle is typically a 3- to 8-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2 heteroatoms) independently selected from sulfur, oxygen, silicon, phosphorus, boron, and / or nitrogen. Examples of 3-membered heterocyclic alkyl groups include, but are not limited to, ethylene oxide, cyclothioethylene, and cycloazoethylene; non-limiting examples of 4-membered heterocyclic alkyl groups include, but are not limited to, acridine, oxadiazolyl, thiobutyl, and silanidine; examples of 5-membered heterocyclic alkyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, imidazolyl, tetrahydropyrazolyl, and silanolyl; examples of 6-membered heterocyclic alkyl groups include, but are not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiaranyl, morpholinyl, piperazine, 1,4-thiaoxane, 1,4-dioxane, thiomorpholinyl, 1,3-dithiaalkyl, and 1,4-dithiaalkyl; and examples of 7-membered heterocyclic alkyl groups include, but are not limited to, azirheptanyl, oxeheptanyl, and thioheptanyl. Monocyclic heterocyclic alkyl groups having 4 or 6 ring atoms are preferred.
[0336] The term "heterocyclic alkenyl" includes cycloalkenyl groups in which one or more carbon atoms are replaced by heteroatoms, specifically, for example, cycloalkenyl groups in which up to three carbon atoms, in one embodiment up to two carbon atoms, or in another embodiment one carbon atom is independently replaced by O, S, or N, provided that at least one cycloalkenyl carbon-carbon double bond is retained. Cyclic groups can exist as monocyclic, bridged, or spirocyclic rings, and can be 3 to 12-membered rings (e.g., 5-, 6-, or 7-membered rings). Examples of heterocyclic alkenyl groups include, but are not limited to, dihydropyrroleyl, dihydrofuranyl, tetrahydropyridyl, tetrahydroazayl, or azaspirooctene.
[0337] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., monocyclic aryl) or a polycyclic aromatic ring system (i.e., polycyclic aryl) having a conjugated π-electron system, having 6 to 20 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 6 to 20-membered aryl). The aryl group is preferably an aryl group having 6 to 14 ring atoms (i.e., 6 to 14-membered aryl) or an aryl group having 6 to 10 ring atoms (i.e., 6 to 10-membered aryl). Monocyclic aryl groups include, for example, phenyl. Non-limiting examples of polycyclic aryl groups include naphthyl, anthracene, phenanthryl, etc. The polycyclic aryl group further includes fusion of a phenyl group with one or more of a heterocyclic group, a cycloalkyl group, a heterocyclic alkenyl group, or a cycloalkenyl group, or fusion of a naphthyl group with one or more of a heterocyclic group, a cycloalkyl group, a heterocyclic alkenyl group, or a cycloalkenyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, wherein the connection point can be at any site of the fused ring, and non-limiting examples include: wait.
[0338] The term "heteroaryl" refers to a monocyclic heteroaryl ring (i.e., monocyclic heteroaryl) or a polycyclic heteroaryl ring system (i.e., polycyclic heteroaryl) having a conjugated π-electron system, wherein the ring contains at least one (e.g., 1, 2, 3, or 4) heteroatoms selected from nitrogen, oxygen, and sulfur (the nitrogen may optionally be oxidized, i.e., to form nitrogen oxides; the sulfur may optionally be oxidized, i.e., to form sulfoxides or sulfones, but excluding -OO-, -OS-, or -SS-), having 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., 5 to 14-membered heteroaryl). The heteroaryl is preferably a heteroaryl having 5 to 10 ring atoms (i.e., 5 to 10-membered heteroaryl), more preferably a heteroaryl having 5 or 6 ring atoms (i.e., 5 or 6-membered heteroaryl).
[0339] Non-limiting examples of the monocyclic heteroaryl groups include: furanyl, thiopheneyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazoleyl, pyrazolyl, triazolyl, tetrazolyl, furazolyl, pyrroleyl, N-alkylpyrroleyl, pyridyl, pyrimidinyl, pyridoneyl, N-alkylpyridoneyl, pyrazinyl, pyridazinyl, etc.
[0340] Non-limiting examples of the aforementioned polycyclic heteroaryl groups include: indolyl, indazole, quinolinyl, isoquinolinyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothiophene, quinazolinyl, benzothiazolyl, carbazole, etc. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused with one or more aryl groups, wherein the bonding site is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaryl ring system. The polycyclic heteroaryl groups also include monocyclic heteroaryl groups fused with one or more of heterocyclic groups, cycloalkyl groups, heterocyclic alkenyl groups, or cycloalkenyl groups, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaryl ring system. Non-limiting examples include: wait.
[0341] The compounds disclosed in this application can exist in specific stereoisomer forms. The term "stereoisomer" refers to isomers with the same structure but different spatial arrangements of atoms. These include cis and trans (or Z and E) isomers, (-)- and (+)- isomers, (R)- and (S)- enantiomers, diastereomers, (D)- and (L)- isomers, tautomers, transisomers, conformational isomers, and mixtures thereof (such as racemic mixtures and mixtures of diastereomers). Substituents in the compounds disclosed in this application may contain additional asymmetric atoms. All such stereoisomers and mixtures thereof are included within the scope of this application. Optically active (-)- and (+)- isomers, (R)- and (S)- enantiomers, and (D)- and (L)- isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. This application discloses an isomer of a compound, which can be prepared by asymmetric synthesis or with chiral auxiliaries. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), it can form a salt of the diastereomer with a suitable optically active acid or base, and then the diastereomer can be resolved by conventional methods known in the art to obtain the pure isomer. Furthermore, the separation of enantiomers and diastereomers is usually accomplished by chromatography.
[0342] In the chemical structure of the compounds described in this disclosure, the bonds... This indicates that the configuration is not specified; that is, if chiral isomers exist in the chemical structure, the bond... It can be Or simultaneously include Two configurations. For all carbon-carbon double bonds, even if only one configuration is named, both the Z-type and E-type are included.
[0343] The compounds disclosed in this application may exist in different tautomer forms, and all such forms are included within the scope of this disclosure. The terms "tautomer" or "tautomer form" refer to a structural isomer that exists in equilibrium and readily transforms from one isomer to another. This includes all possible tautomers, i.e., existing as a single isomer or as a mixture of said tautomers in any proportion. Non-limiting examples include: keto-enols, imine-enamines, lactam-lactamimides, etc. Examples of lactam-lactamimide equilibrium are shown below:
[0344] All tautomers are disclosed within the scope of this application, and the naming of compounds does not exclude any tautomers.
[0345] When one of the variables is selected as empty, it indicates that the two groups it connects to are directly connected, for example... In the middle, L represents spacetime, indicating that the structure is actually
[0346] When the listed linking groups do not specify their linking direction, the linking direction is arbitrary, for example... The connecting group L is -C(=O)-NH-. In this case, -C(=O)-NH- can be connected to cyclohexane and cyclopentane in the same direction as the reading order from left to right to form a compound. Alternatively, cyclohexane and cyclopentane can be connected in the reverse order of reading from left to right to form the compound. The combination of linking groups, substituents, and / or their variants is permitted only if such a combination produces a stable compound.
[0347] The compounds disclosed in this application include all suitable isotopic derivatives thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds disclosed in this application include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, […]. 2 H (deuterium, D) 3 H (tritium, T) 11 C 13 C 14 C 15 N、 17 O、 18 O、 32 p、 33 p、 33S, 34 S, 35 S, 36 S, 18 F, 36 Cl、 82 Br、 123 I, 124 I, 125 I, 129 I and 131 Grade I, with deuterium as the preferred grade.
[0348] Compared to undeuterated drugs, deuterated drugs offer advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, regardless of radioactivity, are included within the scope of this disclosure. Each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium substitution can be partial or complete; partial deuterium substitution refers to the replacement of at least one hydrogen atom with at least one deuterium atom.
[0349] When a position is specifically designated as deuterium (D), the position should be understood as having a deuterium abundance of at least 1,000 times greater than the natural abundance of deuterium (which is 0.015%) (i.e., at least 15% deuterium incorporation). The compounds in the examples having a natural abundance greater than deuterium can be at least 1000 times abundant deuterium (i.e., at least 15% deuterium doping), at least 2000 times abundant deuterium (i.e., at least 30% deuterium doping), at least 3000 times abundant deuterium (i.e., at least 45% deuterium doping), at least 3340 times abundant deuterium (i.e., at least 50.1% deuterium doping), at least 3500 times abundant deuterium (i.e., at least 52.5% deuterium doping), at least 4000 times abundant deuterium (i.e., at least 60% deuterium doping), or at least 4500 times abundant deuterium (i.e., at least 67.5% deuterium doping). The abundance of deuterium is at least 5000 times (i.e., at least 75% deuterium doping), at least 5500 times (i.e., at least 82.5% deuterium doping), at least 6000 times (i.e., at least 90% deuterium doping), at least 6333.3 times (i.e., at least 95% deuterium doping), at least 6466.7 times (i.e., at least 97% deuterium doping), at least 6600 times (i.e., at least 99% deuterium doping), at least 6633.3 times (i.e., at least 99.5% deuterium doping), or higher. Detailed Implementation
[0350] For clarity, this application is further illustrated with examples, but these examples are not intended to limit the scope of this application. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of this application without departing from the spirit and scope thereof. All reagents used in this application are commercially available and can be used without further purification.
[0351] The compounds of this application can be prepared by those skilled in the art of organic synthesis with reference to the routes or methods of the following embodiments. The resulting compounds can be characterized by known instruments or methods, including but not limited to mass spectrometry, nuclear magnetic resonance, etc.
[0352] This application uses the following abbreviations:
[0353] AcOH represents acetic acid; Ar represents argon; BBr3 represents boron tribromide; BH3 represents borane; Boc represents tert-butyloxycarbonyl; br represents a broad peak; ℃ represents degrees Celsius; CD3OD represents deuterated methanol; CDCl3 represents deuterated chloroform; CO represents carbon monoxide; (COCl)2 represents oxalyl chloride; Cs2CO3 represents cesium carbonate; CuCl represents cuprous chloride; CuI represents cuprous iodide; d represents a doublet; DCE represents dichloroethane; DCM represents dichloromethane; Dioxane or 1,4-dioxane represents dioxane; DIPEA or DIEA represents N,N-diisopropylethylamine; DMF represents... Table 1: Dimethylformamide; DMSO represents dimethyl sulfoxide; EA or EtOAc represents ethyl acetate; ESI represents electrospray ionization; FeCl3 represents ferric chloride; g represents grams; H2O represents water; HCl represents hydrochloric acid; HPLC represents high performance liquid chromatography; K2CO3 represents potassium carbonate; KOAc represents potassium acetate; K3PO4 represents potassium phosphate; LDA represents lithium diisopropylamino; LC-MS represents liquid chromatography-mass spectrometry; LiCl represents lithium chloride; LiHMDS represents bis(trimethylsilyl)aminolithium; LiOH represents lithium hydroxide; m represents multiplet; m / z represents mass-to-charge ratio; MeCN or AC N represents acetonitrile; MeOH represents methanol; MeONa represents sodium methoxide; M represents mol; min represents minutes; mg represents milligrams; mL represents milliliters; mmol represents millimoles; N2 represents nitrogen; NaBH4 represents sodium borohydride; Na2CO3 represents sodium carbonate; NaCl represents sodium chloride; NaHCO3 represents sodium bicarbonate; NaH represents sodium hydride; NaOH represents sodium hydroxide; Na2SO4 represents sodium sulfate; NBS represents N-bromosuccinimide; n-BuLi represents n-butyllithium; NH4Cl represents ammonium chloride; NIS represents N-iodosuccinimide; PE represents petroleum ether; Pd(dppf) Cl2 represents [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) dichloride; Pd(OAc)2 represents palladium acetate; THF represents tetrahydrofuran; tBuOK represents potassium tert-butoxide; rt or RT represents room temperature; Xantphos represents 4,5-bis(diphenylphosphine)-9,9-dimethyloxanthracene; X-Phos represents 2-biscyclohexylphosphine-2',4',6'-triisopropylbiphenyl; XPhosPdG2 represents chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II); UV represents ultraviolet light.
[0354] Example 1: Preparation of Compound 1
[0355] Synthesis of Compound 1-1
[0356] 2-Bromo-6-hydroxybenzaldehyde (25 g) and KOH (34.89 g) were dissolved in ACN / H₂O (V / V = 10:1, 622 mL). Diethyl bromofluoromethyl phosphate (39.85 g) was slowly added dropwise at 0 °C, and the mixture was stirred at 0 °C for 0.5 hours. After adjusting the pH to approximately 5 with 1 M HCl, the mixture was extracted three times with EA (500 mL). The combined organic phases were washed with brine (1500 mL) and dried over anhydrous Na₂SO₄. The residue was concentrated and purified to give compound 1-1 (15.5 g).
[0357] 1 H-NMR (400MHz, CDCl3) δ10.35(s,1H),7.58(dd,J=8.1,1.0Hz,1H),7.42(t,J=8.2Hz,1H),7.26(d,J=9.1Hz,1H),6.61(t,J=73.4Hz,1H).
[0358] Synthesis of Compounds 1-2
[0359] A mixture of tetraisopropyl titanate (304.12 g) and cyclobutanone (50 g) in THF (400 mL) was stirred for 10 minutes. Tert-butylsulfinamide (69.17 g) was then added, and the reaction mixture was stirred at 70 °C for 5 hours. After the reaction was complete, water (200 mL) was added, the mixture was filtered, and the filtrate was collected, concentrated, and purified to give compounds 1-2 (41.00 g).
[0360] 1 H-NMR (400MHz, DMSO-d6) δ3.41-3.30(m,1H),3.24-2.99(m,3H),2.09-1.96(m,2H),1.15(d,J=8.8Hz,9H).
[0361] Synthesis of compounds 1-3
[0362] At -78°C, n-BuLi (1.6M, 148.97mL) was added dropwise to a dry toluene (1200mL) solution of 67.90g of 2-iodo-5-bromopyrimidine and reacted at -78°C for 40 minutes. Then, a dry toluene (120mL) solution of 41.3g of compound 1-2 was added. The mixture was stirred at -78°C for 40 minutes, then heated to 0°C and reacted for another 2 hours. Saturated NH4Cl (1500mL) was added to the reaction system, and the mixture was extracted twice with EA (1000mL). The organic phase was concentrated and purified to give compound 1-3 (13.00g).
[0363] LC-MS(ESI)m / z:[M+H] + =332.1
[0364] Synthesis of compounds 1-4
[0365] Compounds 1-3 (800 mg), pinacol borate (742.77 mg), and Pd(dppf)Cl2 (177.94 mg) were dissolved in 1,4-dioxane (8 mL). KOAc (717.65 mg) was added, the mixture was heated to 100 °C, stirred for 1 hour, concentrated, and then PE was added to slurry. The mixture was filtered, the filter cake was washed with PE, and the filtrate was concentrated to obtain compounds 1-4 (600.00 mg).
[0366] LC-MS(ESI)m / z:[M+H] + =298.2
[0367] Synthesis of compounds 1-6
[0368] Compound 4-benzyloxypyridine (25 g) was dissolved in anhydrous DCM (250 mL), and compound 2,4-dinitrophenylhydroxylamine (53.75 g) was added. The mixture was stirred at room temperature for 18 hours. After filtration and concentration, compounds 1-5 (51.00 g) were obtained. Compounds 1-5 (11 g) and compound 2,2-difluorovinyl-4-methylbenzenesulfonate (20.11 g) were dissolved in DMF (200 mL). At 0 °C, potassium carbonate (17.01 g) was added, and the mixture was stirred at room temperature for 1 hour. After stirring at 90 °C for another 5 hours, the mixture was quenched with water (200 mL) and extracted with ethyl acetate (200 x 2 mL). The organic phases were combined, dried, concentrated, and purified to obtain compounds 1-6 (2.00 g).
[0369] LC-MS[M+1] + =243.2
[0370] 1 H-NMR (400MHz, CDCl3) δ8.09 (d, J = 7.7Hz, 1H), 7.48-7.35 (m, 5H), 6.73-6.69 (m, 1H), 6.51 (dd, J=7.4, 2.7Hz, 1H), 5.82 (dd, J=5.2, 0.5Hz, 1H), 5.11-5.02 (m, 2H).
[0371] Synthesis of compounds 1-7
[0372] Compounds 1-6 (2 g) were dissolved in ACN (40 mL), and NIS (3.71 g) was added in portions. The mixture was stirred at room temperature for 2 hours. After quenching with saturated sodium sulfite (10 mL), the mixture was extracted with ethyl acetate (30 x 3 mL). The organic phases were combined, dried, concentrated, and purified to give compounds 1-7 (2.00 g).
[0373] LC-MS[M+1] + =369.1
[0374] Synthesis of compounds 1-8
[0375] Compounds 1-7 (2.1 g) and HMPA (3.07 g) were added to tetrahydrofuran (35.62 mL). Under nitrogen protection, the mixture was cooled to -30 °C, and isopropyl magnesium chloride-lithium chloride complex (1.3 M, 8.78 mL) was slowly added dropwise. The mixture was stirred for 30 minutes, followed by the addition of a tetrahydrofuran solution of compound 1-1 (1.86 g) (3.96 mL). The temperature was maintained at -30 °C for 0.5 hours, then raised to 0 °C and stirred for 1 hour. The reaction solution was poured into saturated ammonium chloride (10 mL) and extracted with EA (10 x 3 mL). The organic phases were combined, and the combined organic layer was washed with brine (10 mL), dried, concentrated, and purified to obtain compound 1-8 (1.3 g).
[0376] LC-MS[M+1] + =475.2
[0377] Synthesis of compounds 1-9
[0378] Compounds 1-8 (2.2 g) and indium bromide (1.58 g) were dissolved in dichloromethane (40 mL). TMSCN (4.42 g) was added at 0 °C, and the mixture was brought to room temperature and stirred for 2 hours. The solution was then concentrated and purified to obtain compounds 1-9 (1.50 g).
[0379] LC-MS[M+1] + =502.2
[0380] Synthesis of compounds 1-10
[0381] Compound 1-9 (1.5 g) was dissolved in tetrahydrofuran (30 mL). Borane tetrahydrofuran (1 M, 8.96 mL) was added at 0 °C, the mixture was brought to room temperature, stirred for 2 hours, quenched with methanol (10 mL), and concentrated and purified to obtain compound 1-10 (930.00 mg).
[0382] LC-MS[M+1] + =506.3
[0383] Synthesis of compounds 1-11
[0384] Compound 1-10 (2.1 g) was stirred at 150 °C with a gentle heat for 18 hours, then cooled to room temperature. Purification yielded compound 1-11 (350.00 mg). LC-MS [M+Na] + =486.2
[0385] Synthesis of compounds 1-12
[0386] Compound 1-11 (200 mg) was dissolved in AcOH / H2O (4 mL, 10 / 1), and NaNO2 (42.57 mg) was added at 10 °C. The mixture was then heated to room temperature and stirred for 2 hours. After quenching with water (10 mL), the mixture was extracted with ethyl acetate (30 x 3 mL). The organic phases were combined, dried, concentrated, and purified to give compound 1-12 (190.00 mg).
[0387] LC-MS[M+Na] + =485.2
[0388] Synthesis of compounds 1-13
[0389] Compound 1-12 (190 mg) was dissolved in THF / H2O (10 mL, 5 / 1). Zn (95.17 mg) was added at 0 °C, and the mixture was brought to room temperature and stirred for 2 hours. After quenching with water (10 mL), the mixture was extracted with ethyl acetate (30 x 3 mL). The organic phases were combined, dried, concentrated, and purified to give compound 1-13 (100.00 mg).
[0390] LC-MS[M+1] + =501.3
[0391] Synthesis of compounds 1-14
[0392] Compound 1-13 (90 mg) was dissolved in dioxane (25 mL), and potassium carbonate (49.55 mg), Pd2dba3 (32.85 mg), and XantPhos (20.75 mg) were added. The mixture was purged with CO gas three times, and the reaction solution was placed at 110 °C for 18 hours. After concentration and purification, compound 1-14 (40.00 mg) was obtained.
[0393] LC-MS[M+1] + =449.3
[0394] 1 H-NMR (400MHz, DMSO-d6) δ10.34(s,1H),8.41(t,J=8.5Hz,1H),8.09(dd,J=7.7,1.6Hz,1H),7.46-7.33(m,8H),6.63(d,J=2.2H z,1H),6.54-6.50(m,1H),5.11(t,J=12.4Hz,2H),4.82(d,J=4.9Hz,1H),4.47(dd,J=12.6,4.9Hz,1H),3.80(d,J=12.6Hz,1H).
[0395] Synthesis of compounds 1-15
[0396] Compounds 1-14 (40 mg, 89.20 μmol) and CD3I (51.72 mg, 356.81 μmol) were dissolved in DMF (2 mL). NaH (7.85 mg, 60% purity) was added at 0 °C, and the mixture was stirred at room temperature for 1 hour. After quenching with saturated ammonium chloride (20 mL), the mixture was extracted with ethyl acetate (20 x 3 mL). The organic phases were combined to give compound 1-15 (42.00 mg).
[0397] LC-MS[M+1] + =466.3
[0398] Synthesis of compounds 1-16
[0399] Compound 1-15 (32 mg) and Pd / C (25.05 mg / L) were dissolved in methanol (10 mL) and stirred at room temperature for 2 hours. The mixture was then concentrated and purified to give compound 1-16 (20.00 mg).
[0400] LC-MS[M+1] + =376.2
[0401] Synthesis of compounds 1-17
[0402] Compound 1-16 (10 mg) and Tf₂O (11.27 mg) were dissolved in dichloromethane (1 mL). DIEA (10.31 mg, 79.93 μmol) was added at 0 °C, and the mixture was stirred at 20 °C for 1 hour. After quenching with water (10 mL), the mixture was extracted with dichloromethane (10 x 3 mL). The organic phases were combined and purified to give compound 1-17 (15.00 mg).
[0403] LC-MS[M+1] + =508.2
[0404] Synthesis of compounds 1-18
[0405] Compound 1-17 (10 mg / L) was dissolved in a mixed solution of Dioxane / H₂O (1 mL), and then compound 1-4 (14.95 mg), XPhos-Pd-G₂ (1.55 mg), XPhos (1.88 mg), and K₃PO₄ (8.36 mg) were added. The mixture was purged with nitrogen and stirred at 110 °C for 4 hours. The reaction solution was concentrated and purified to obtain compound 1-18 (12.00 mg).
[0406] LC-MS[M+1] + =611.5
[0407] Synthesis of Compound 1
[0408] Compound 1-18 (12 mg) was dissolved in a THF / H2O (0.3 mL) mixture, and iodine (7.48 mg) was added. The mixture was purged with nitrogen and stirred at 50 °C for 1 hour. After quenching with saturated sodium sulfite (10 mL), the mixture was extracted with ethyl acetate (10 x 3 mL). The organic phases were combined, dried, concentrated, and purified to give compound 1 (8.20 mg).
[0409] LC-MS[M+1] + =507.3
[0410] 1 H-NMR (400MHz, DMSO-d6) δ9.14(d,J=11.5Hz,2H),8.76(dd,J=7.4,0.8Hz,1H),8.13(dd,J=7.4,1.9Hz,1H),7.77-7.27(m ,5H),4.94(d,J=4.9Hz,1H),4.59(dd,J=12.6,4.9Hz,1H),4.00(d,J=12.6Hz,1H),2.68-2.60(m,2H),2.19-1.79(m,4H).
[0411] Examples 2 and 3
[0412] Compound 1 was chirally purified under SFC conditions in a CHIRALPAK column (250*30mm, IB, 10μm; flow rate 25mL / min; mobile phase: 60% ACN (0.2% NH3·MeOH) + 40% IPA (0.2% NH3·MeOH)) to obtain compound 2 (shorter retention time) and compound 3 (longer retention time).
[0413] Compound 2
[0414] LC-MS[M+1]+=507.38
[0415] 1 H NMR (400MHz, DMSO-d6) δ9.19(s,2H),8.78(d,J=7.4Hz,1H),8.15(d,J=7.7Hz,1H),7.80-7.59(m,2H),7.44-7.28(m,3H),4.97(d,J=4.7H z,1H),4.61(dd,J=12.9,5.0Hz,1H),4.02(d,J=12.9Hz,1H),3.29-3.23(m,1H),2.71-2.63(m,1H),2.28-2.19(m,2H),2.08-1.88(m,2H).
[0416] Compound 3
[0417] LC-MS[M+1]+=507.48
[0418] 1 H NMR (400MHz, DMSO-d6) δ9.18 (s, 2H), 8.78 (d, J = 7.4Hz, 1H), 8.15 (dd, J = 7.4, 2.0Hz,1H),7.80-7.59(m,2H),7.43-7.37(m,2H),7.30(dd,J=7.4,2.1Hz,1H) ,4.97(d,J=4.8Hz,1H),4.61(dd,J=12.9,4.9Hz,1H),4.02(d,J=12.7Hz,1H) ,3.28-3.24(m,1H),2.70-2.63(m,1H),2.27-2.20(m,2H),2.08-1.95(m,2H).
[0419] Example 4
[0420] Following the synthesis and purification methods of compound 1, compound 4 was synthesized.
[0421] LC-MS[M+1] + =525.4
[0422] 1 H-NMR (400MHz, DMSO-d6) δ9.31(d,J=5.2Hz,2H),8.84(dd,J=7.4,0.8Hz,1H),8.78(s,2H),8.26(dd,J=9.3,5.5Hz,1H),7.70(s,1H),7.51(s,1H),7.42 -7.34(m,2H),4.96(d,J=4.9Hz,1H),4.63(dd,J=12.9,4.9Hz,1H),4.02(d, J=12.9Hz,1H),2.76-2.67(m,2H),2.56(d,J=8.5Hz,2H),2.23-2.15(m,2H).
[0423] Examples 5 and 6
[0424] Compound 4 was chirally purified under SFC conditions in a CHIRALPAK column (250*30mm, IB, 10μm; flow rate 25mL / min; mobile phase: 70% ACN (0.2% NH3·MeOH) + 30% EtOH (0.2% NH3·MeOH)) to yield compound 5 (shorter retention time) and compound 6 (longer retention time).
[0425] Compound 5
[0426] 1 H NMR(400MHz, DMSO-d6)δ9.18(s,2H),8.78(d,J=7.4Hz,1H),8.31–8.21(m,1H),7.72-7.48(m,2H),7.43–7.30(m,2H),4.96(d, J=4.9Hz,1H),4.62(dd,J=12.9,5.0Hz,1H),4.00(d,J=12.8Hz,1H),2.70-2.62(m,2H),2.29-2.23(m,2H),2.09-1.94(m,2H).
[0427] Compound 6
[0428] 1 H NMR(400MHz, DMSO-d6)δ9.17(s,2H),8.78(d,J=7.3Hz,1H),8.25(dd,J=9.3,5.6Hz,1H),7.71–7.50(m,2H),7.42–7.29(m,2H),4.9 6(d,J=4.9Hz,1H),4.61(dd,J=12.9,5.0Hz,1H),3.99(d,J=12.9Hz,1H),2.67–2.60(m,2H),2.27-2.21(m,2H),2.07–1.92(m,2H).
[0429] Example 7
[0430] Following the synthesis and purification methods of compound 1, compound 7 was synthesized.
[0431] LC-MS[M+1]+=520.8
[0432] 1H-NMR (400MHz, CDCl3) δ8.96(s,2H),8.43(d,J=6.6Hz,1H),8.30(d,J=8.8Hz,1H),7.51(d,J=5.5Hz,1H),6.94(d,J= 9.1Hz, 1H), 6.86 (d, J = 5.5Hz, 1H), 4.71-4.63 (m, 2H), 3.93 (d, J = 12.1Hz, 1H), 2.89-2.85 (m, 3H), 2.43-2.33 (m, 2H).
[0433] Examples 8 and 9
[0434] Compound 7 was chirally purified under SFC conditions in a CHIRALPAK column (250*30mm, IB, 10μm; flow rate 25mL / min; mobile phase: 95% ACN (0.2% NH3·MeOH) + 5% EtOH (0.2% NH3·MeOH)) to obtain compound 8 (shorter retention time) and compound 9 (longer retention time).
[0435] Compound 8
[0436] LC-MS[M+1] + =521.45
[0437] 1 H NMR (400MHz, DMSO-d6) δ9.17(s,2H),8.76(d,J=7.4Hz,1H),8.15(d,J=8.9Hz,1H),7.77(d,J=2.0Hz,1H),7.30(t,J=8.5Hz,2H ),4.76(d,J=4.4Hz,1H),4.64-4.57(m,1H),4.07(d,J=12.7Hz,1H),2.70-2.60(m,2H),2.23-2.13(m,2H),2.05-1.84(m,2H).
[0438] Compound 9
[0439] LC-MS[M+1] + =521.06
[0440] 1H NMR (400MHz, DMSO-d6) δ9.17(s,2H),8.76(d,J=7.4Hz,1H),8.15(d,J=8.9Hz,1H),7.77(d,J=1.9Hz,1H),7.36-7.27(m,2H),4.77 (d,J=4.4Hz,1H),4.59(dd,J=12.7,4.6Hz,1H),4.07(d,J=12.7Hz,1H),2.69-2.60(m,2H),2.23-2.15(m,2H),2.08-1.87(m,2H).
[0441] Example 10
[0442] Compounds 1-16 were chirally purified under SFC conditions on a Chiralpak IG column (250*30mm, ID, 10μm; flow rate 25mL / min; mobile phase: 50% HEX + 50% Ethanol) to obtain compound 1-16A (shorter retention time) and compound 1-16B (longer retention time).
[0443] Synthesis of compound 1-17A
[0444] Compound 1-16A (100 mg) and Tf₂O (112.7 mg) were dissolved in dichloromethane (10 mL). DIEA (103.1 mg) was added at 0 °C, and the mixture was stirred at 20 °C for 1 hour. After quenching with water (50 mL), the mixture was extracted with dichloromethane (3 x 50 mL). The organic phases were combined and purified to give compound 1-17A (150 mg).
[0445] LC-MS[M+1] + =508.2
[0446] Synthesis of compound 10-2
[0447] Compound 10-1 (30 mg), bis-pinacolborate (22.57 mg), and KOAc (15.86 mg) were dissolved in dioxane (1 mL), and Pd(dppf)Cl2 (5.90 mg) was added. The mixture was heated to 90 °C and stirred for 2 hours. The reaction solution was used directly in the next step.
[0448] LC-MS[M+1] + =336.9
[0449] Synthesis of compound 10-3
[0450] Add water (0.1 ml) to the reaction solution of compound 10⁻², then add 1-17A (20 mg), XPhos-Pd-G₂ (3.09 mg), XPhos (3.75 mg), and K₃PO₄ (16.71 mg) sequentially. Purge with nitrogen and stir at 100 °C for 2 hours. Purify to obtain compound 10⁻³ (20.00 mg). LC-MS [M+1] + =649.8
[0451] Synthesis of Compound 10
[0452] Compound 10-3 (20 mg) was dissolved in tetrahydrofuran (2 mL) and water (0.4 mL), and elemental iodine (7.84 mg) was added. The mixture was stirred at 50 °C for 1 hour. The reaction solution was poured into a saturated sodium sulfite aqueous solution (10 mL), extracted with ethyl acetate (2 x 10 mL), and the organic phases were combined, dried, concentrated, and purified to give compound 6 (4.93 mg).
[0453] LC-MS[M+1] + =545.8
[0454] 1 H-NMR (400MHz, CDCl3) δ8.98(d,J=7.1Hz,2H),8.38(dd,J=31.5,7.0Hz,2H),7.57(s,1H),7.28(d,J=8.0Hz,1H),7.21(d,J=8.0Hz,1H),6.97-6 .60(m,2H),5.00(d,J=4.7Hz,1H),4.64(dd,J=12.6,4.9Hz,1H),3.90(d,J=12.6Hz,1H),3.35(s,2H),3.00(d,J=13.5Hz,2H),1.78-1.69(m,3H)
[0455] Example 11
[0456] Compound 11 was synthesized using the same synthesis and purification methods as compound 10.
[0457] LC-MS[M+1] + =545.9
[0458] 1H-NMR (400MHz, CDCl3) δ8.95(s,2H),8.39(d,J=33.8Hz,2H),7.58(s,1H),7.24(d,J=13.7Hz,2H),6.96-6.59(m,2 H), 5.01 (s, 1H), 4.67 (s, 1H), 3.91 (d, J = 10.2Hz, 1H), 3.44 (d, J = 11.3Hz, 2H), 2.34 (d, J = 10.7Hz, 2H), 1.81 (s, 3H).
[0459] Example 12
[0460] Compound 12 was synthesized using the same synthesis and purification methods as compound 10.
[0461] LC-MS[M+1] + =547.4
[0462] 1 H-NMR (400MHz, DMSO-d6) δ9.18(s,2H),8.77(d,J=7.4Hz,1H),8.12(dd,J=7.4,1.9Hz,1H),7.77-7.58(m,2H),7.40-7.35(m,2H),7.28(dd,J=7.4,1 .9Hz,1H),6.19(s,1H),4.94(d,J=4.7Hz,1H),4.61-4.58(m,1H),4.00(d, J=12.6Hz,1H),2.67(t,J=1.8Hz,2H),2.33(t,J=1.8Hz,2H),1.44(s,3H).
[0463] Example 13
[0464] Compound 13 was synthesized using the same synthesis and purification methods as compound 10.
[0465] LC-MS[M+1] + =547.4
[0466] 1H-NMR (400MHz, CDCl3) δ8.99 (s, 2H), 8.44 (d, J = 7.1Hz, 1H), 8.35 (dd, J = 8.2, 1.4Hz,1H),7.58(d,J=1.1Hz,1H),7.31-7.27(m,1H),7.22(d,J=8.0Hz,1H),6 .97-6.60(m,2H),5.01(d,J=4.7Hz,2H),4.66(dd,J=12.5,5.1Hz,1H),3.91(d ,J=12.4Hz,1H),3.42(d,J=13.2Hz,2H),2.53(d,J=13.5Hz,2H),1.83(s,3H).
[0467] Example 14
[0468] Compound 14 was synthesized using the same synthesis and purification methods as compound 10.
[0469] LC-MS[M+1] + =553.9
[0470] 1 H-NMR (400MHz, CDCl3) δ8.61 (s, 1H), 8.38-8.32 (m, 2H), 7.60-7.52 (m, 2H), 7.28 (d, J = 8.2Hz, 1H), 7.25-7.19 (m, 2H), 7.00-6.60 (m, 2H), 4.98 (d, J = 4.9Hz, 1H), 4.63 (dd, J = 12.5, 4.8Hz, 1H), 3.89 (d, J = 12.6Hz, 1H), 2.92 (d, J = 12.6Hz, 2H), 2.74 (s, 2H), 1.41 (s, 3H).
[0471] Example 15
[0472] Compound 15 was synthesized using the same synthesis and purification methods as compound 10.
[0473] LC-MS[M+1] + =553.9
[0474] 1H-NMR (400MHz, CDCl3) δ8.63(s,1H),8.36(q,J=7.8Hz,2H),7.63-7.52(m,2H),7.29(s,1H),7.20(d,J=7.7Hz,1H),6.98(d,J=15.7Hz,1 H),6.82-6.77(m,1H),4.99(d,J=4.9Hz,1H),4.64(dd,J=12.6,4.9Hz,1H),3.90(d,J=12.6Hz,1H),3.04(d,J=49.5Hz,4H),1.69(s,3H).
[0475] Example 16
[0476] Compound 16 was synthesized using the same synthesis and purification methods as compound 10.
[0477] LC-MS[M+1] + =507.8
[0478] 1 H-NMR (400MHz, CDCl3) δ8.35-8.30(m,3H),7.48(s,1H),7.32(d,J=27.2Hz,1H),7.24(t,J=1.8Hz,1H),7.20(d,J=7.7Hz,1H),7.13-6.57( m,1H),6.80-6.78(m,1H),4.97(d,J=4.9Hz,1H),4.63(dd,J=12.6,4.9Hz,2H),4.51(d,J=9.9Hz,1H),3.89(d,J=12.6Hz,1H),1.71(s,3H).
[0479] Example 17
[0480] Following the synthesis and purification methods of compound 10, compound 17 was synthesized.
[0481] LC-MS[M+1] + =507.9
[0482] 1H-NMR (400MHz, CDCl3) δ8.37-8.33(m,3H),7.52-7.49(m,1H),7.27(s,1H),7.25-7.23(m,1H),7.20(d,J=6.9Hz,1H),6.94 -6.57(m,1H),6.82(dd,J=7.4,1.9Hz,1H),4.98(d,J=4.7Hz,1H),4.66-4.45(m,3H),3.89(d,J=12.4Hz,1H),1.67(s,3H).
[0483] Example 18
[0484] Compound 18 was synthesized using the same synthesis and purification methods as compound 10.
[0485] LC-MS[M-NH2] + =493.9
[0486] 1 H-NMR (400MHz, CDCl3) δ8.41-8.32(m,3H),7.50(d,J=15.4Hz,1H),7.29(d,J=9.1Hz,1H),7.25-7.17(m,2H),6. 94-6.57(m,2H),5.00-4.96(m,1H),4.84(s,1H),4.66-4.60(m,1H),4.51(d,J=10.4Hz,1H),3.91-3.86(m,1H).
[0487] Example 19
[0488] Compound 19 was synthesized using the same synthesis and purification methods as compound 10.
[0489] LC-MS[M+1] + =511.3
[0490] 1H-NMR (400MHz, DMSO-d6) δ8.71-8.69(m,1H),8.11(dd,J=7.0,2.3Hz,1H),7.76-7.72(m,1H),7.56(d,J=7.1Hz,2H),7.39-7.32(m,2H),7.1 7-6.57(m,1H),4.91(d,J=4.7Hz,1H),4.73(d,J=11.0Hz,1H),4.64(d,J=11.0Hz,1H),4.56(dd,J=12.9,4.9Hz,1H),3.97(d,J=12.6Hz,1H).
[0491] Example 20
[0492] Compound 20 was synthesized using the same synthesis and purification methods as compound 10.
[0493] LC-MS[M+1] + =513.4
[0494] 1 H-NMR (400MHz, DMSO-d6) δ8.72-8.70(m,4H),8.54(d,J=1.6Hz,1H),8.12-8.09(m,1H),7.76-7.73(m,1H),7.58-7.55(m,1H) ,7.39-7.32(m,2H),7.17(dd,J=7.4,2.2Hz,1H),4.91(d,J=4.7Hz,1H),4.57(dd,J=12.8,5.1Hz,1H),3.98(d,J=12.6Hz,1H).
[0495] Example 21
[0496] Compound 21 was synthesized using the same synthesis and purification method as compound 10.
[0497] LC-MS[M+1] + =513.4
[0498] 1H-NMR (400MHz, DMSO-d6) δ8.72-8.70(m,4H),8.55(d,J=1.9Hz,1H),8.12(dd,J=7.0,2.6Hz,1H),7.76-7.74(m,1H),7.57(d,J=7.1H z,1H),7.39-7.32(m,2H),7.18(dd,J=7.4,1.9Hz,1H),4.92(d,J=4.9Hz,1H),4.57(dd,J=12.8,5.1Hz,1H),3.98(d,J=12.9Hz,1H).
[0499] Example 22
[0500] Following the synthesis and purification methods of compound 10, compound 22 was synthesized.
[0501] LC-MS[M-NH2] + =503.8
[0502] 1 H-NMR (400MHz, CDCl3) δ8.97-8.92(m,2H),8.43-8.33(m,2H),7.57(t,J=1. 0Hz,1H),7.29(d,J=8.0Hz,1H),7.21(d,J=7.7Hz,1H),6.95-6.58(m,1H),6. 86(dd,J=7.3,2.1Hz,1H),5.00(d,J=4.7Hz,1H),4.65(dd,J=12.6,4.9Hz,1H ),3.90(d,J=12.6Hz,1H),1.59(s,3H),1.45-1.36(m,1H),0.50-0.33(m,4H)
[0503] Examples 23 and 24
[0504] Following the synthesis and purification method of compound 1, compounds 23 and 24 were synthesized. Under SFC conditions, they were chirally purified in a CHIRALPAK column (250*30mm, IB, 10μm; flow rate 25mL / min; mobile phase: 80% ACN (0.2% NH3·MeOH) + 20% IPA (0.2% NH3·MeOH)) to obtain compound 23 (shorter retention time) and compound 24 (longer retention time).
[0505] Compound 23
[0506] LC-MS[M+1] + =530.3
[0507] 1 H NMR(400MHz, DMSO-d6)δ8.71(d,J=7.4Hz,1H),8.13(dd,J=7.7,1.8Hz,1H),7.91–7.84(m,1H),7.78–7.59(m,4H),7.41–7.33(m,2H) ,7.20(dd,J=7.4,2.1Hz,1H),4.94(d,J=4.8Hz,1H),4.59(dd,J=12.8,4.9Hz,1H),3.99(d,J=12.8Hz,1H),1.77(s,3H),1.73(s,3H).
[0508] Compound 24
[0509] LC-MS[M+1] + =530.3
[0510] 1 H NMR (400MHz, DMSO-d6) δ8.71(d,J=7.4Hz,1H),8.13(dd,J=7.7,1.8Hz,1H),7.91–7.59(m,5H),7.41–7.33(m,2H),7.20(dd ,J=7.4,2.2Hz,1H),4.94(d,J=4.8Hz,1H),4.59(dd,J=12.7,4.9Hz,1H),3.99(d,J=12.8Hz,1H),1.77(s,3H),1.73(s,3H).
[0511] Examples 25 and 26
[0512] Following the synthesis and purification method of compound 10, compounds 25 and 26 were synthesized. Under SFC conditions, they were chirally purified in a Chiral PAK column (250*30mm, IB, 10μm; flow rate 25mL / min; mobile phase: 60% ACN (0.2% NH3·MeOH) + 40% IPA (0.2% NH3·MeOH)) to obtain compound 23 (shorter retention time) and compound 24 (longer retention time).
[0513] Compound 25
[0514] LC-MS[M+1] + =533.66.
[0515] 1H NMR(400MHz, DMSO-d6)δ9.17(s,2H),8.77(d,J=7.3Hz,1H),8.15(dd,J=7.6,1.9Hz,1H),7.81–7.36(m,4H),7.30(dd,J=7.3,2.1Hz,1H),4.97(d, J=4.8Hz,1H),4.61(dd,J=12.7,4.9Hz,1H),4.01(d,J=12.8Hz,1H),2.9 0–2.81(m,2H),2.31–2.24(m,2H),0.58-0.53(m,2H),0.45-0.40(m,2H).
[0516] Compound 26
[0517] LC-MS[M+1] + =533.03.
[0518] 1 H NMR(400MHz, DMSO-d6)δ9.19(s,2H),8.78(d,J=7.4Hz,1H),8.15(dd,J=7.5,1.9Hz,1H),7.82–7.35(m,4H),7.31(dd,J=7.4,2.1Hz,1H),4.97(d, J=4.8Hz,1H),4.61(dd,J=12.7,4.9Hz,1H),4.02(d,J=12.8Hz,1H),2.8 8-2.83(m,2H),2.34-2.30(m,2H),0.60-0.54(m,2H),0.47-0.42(m,2H).
[0519] Examples 27 and 28
[0520] Following the synthesis and purification method of compound 10, compounds 27 and 28 were synthesized. Under SFC conditions, they were chirally purified in a Chiralpak column (250*30mm, IB, 10μm; flow rate 25mL / min; mobile phase: 60% ACN (0.2% NH3·MeOH) + 40% IPA (0.2% NH3·MeOH)) to obtain compound 27 (shorter retention time) and compound 28 (longer retention time).
[0521] Compound 27
[0522] LC-MS[M+1] + =565.16.
[0523] 1H NMR (400MHz, DMSO-d6) δ9.33(s,2H),8.82(d,J=7.4Hz,1H),8.80(s,2H),8.15(dd,J=7.3,2.2Hz,1H),7.79–7.35(m,5H),4.97(d,J=4.7Hz,1H) ,4.62(dd,J=12.8,5.0Hz,1H),4.03(d,J=12.8Hz,1H),3.46(s,2H),3.27(s,3H),2.77(d,J=13.5Hz,2H),2.29(d,J=13.6Hz,2H),1.36(s,3H).
[0524] Compound 28
[0525] LC-MS[M+1] + =565.15.
[0526] 1 H NMR (400MHz, DMSO-d6) δ9.34(s,2H),8.83(d,J=7.8Hz,1H),8.59(s,2H),8.16(dd,J=7.2,2.3Hz,1H),7.79–7.34(m,5H),4.98(d,J=4.7 Hz,1H),4.63(dd,J=12.8,4.9Hz,1H),4.04(d,J=12.8Hz,1H),3.44(s,5H),2.63(d,J=13.6Hz,2H),2.49(d,J=13.3Hz,2H),1.26(s,3H).
[0527] Biological evaluation
[0528] The structure of compound A is
[0529] Compound A was prepared using the method disclosed in Example 14 on page 200 of the specification of patent (WO2025038927).
[0530] Test Example 1. TNFα Binding Ability Experiment
[0531] 1. Experimental Materials
[0532] 2. Experimental Procedure
[0533] The inhibition of TNFα binding by the fluorescent conjugate in vitro was tested using a fluorescence polarization method. In the experiment, the initial concentration of the test compound for inhibiting the binding of the fluorescent conjugate to TNFα was 1000 nM, diluted 3-fold, for a total of 9 concentrations, and tested in replicates.
[0534] Prepare a 1x fluorescence polarization buffer (TBST: 20mM Tris, 137μM NaCl, pH 7.6±0.1, Tween-20: 0.05%). Serially dilute the test compound and positive control to 3x their working concentration using TBST buffer, starting at 3μM and using 9 3x serial dilutions. Add 20μl of TNFα (225nM) diluted to 3x working concentration using TBST buffer and 20μl of the compound diluted to 3x working concentration to a 384-well black flat-bottomed non-binding microplate. Incubate at 37°C for 1 hour. Dilute the experimental probe to 3x its working concentration (30nM) using TBST buffer. Add 20μl of the experimental probe to the incubated TNFα and probe mixture. Incubate the reaction mixture at 37°C for 20 hours. The fluorescence intensity of the experiment was read using the i3x multi-functional microplate reader.
[0535] The experimental results were analyzed using formulas:
[0536] 1)G=P / S*[(1-27 / 1000) / (1+27 / 1000)]
[0537] S: Average vertical polarization value of the experimental probe
[0538] P: Average horizontal polarization value of the experimental probe
[0539] 2)
[0540] mP: Fluorescence polarization value
[0541] Ipara: Parallel fluorescence intensity
[0542] Iperp: Vertical fluorescence intensity
[0543] 3) Z-factor = 1 - (3*(σ) p +σ n ) / |(μ p -μ n )|)
[0544] σ p Standard deviation of positive control
[0545] σ n Standard deviation of negative control
[0546] μ p : Average value of positive control
[0547] μ n : Average value of negative control
[0548] IC of the compound 50The value is calculated using log(inhibitor) vs. response -- Variable slope (4-parameter logical model) in GraphPad Prism.
[0549] The TNFα binding capacity of the disclosed compound was determined through the above experiments.
[0550] Conclusion: The compound disclosed in this study has a strong binding affinity to TNFα.
[0551] Test Example 2. Inhibition of TNFα-induced NF-κB activation
[0552] 1. Experimental Materials
[0553] 2. Experimental Procedure
[0554] The in vitro inhibition of TNFα-induced reporter gene expression in cells was tested using an enzyme colorimetric method. In the experiment, the starting concentration for testing the inhibitory activity of the test compound against the TNFα-induced NF-κB signaling pathway in cells was 10,000 nM, diluted 5-fold, for a total of 9 concentrations, and tested in replicates.
[0555] Prepare complete cell culture medium (RPMI-1640 + 10% heat-inactivated fetal bovine serum + 100 μg / ml Normocin + 10 μg / ml blasticidin + 100 μg / ml Zeocin) and dilute TNFα to its working concentration of 4 times: 200 pM. Dilute the test compound and positive control to their working concentrations of 4 times using complete culture medium, starting at 40 μM and serially diluting 5-fold for a total of 9 concentrations. Mix equal volumes of TNFα and the drug and incubate at 37°C for 1 hour. Centrifuge ISRE-Luc / NFκB-SEAP / THP-1 and resuspend in complete culture medium. Seed 1 x 10⁵ cells per well in a 96-well cell culture plate, with a volume of 100 μl per well. Add 100 μl of the pre-incubated TNFα and drug mixture to the cells and incubate at 37°C for 20 hours. Centrifuge the cells and transfer 25 μl of the supernatant to a new 96-well flat-bottomed clear microplate. Add 175 μl of QUANTI-BLUE assay reagent to the cell supernatant. After a simple centrifugation of the microplate, incubate at 37°C for 2 hours. Use after simple centrifugation of the microplate. The i3x multi-functional microplate reader reads and records the absorbance at a wavelength of 620 nm.
[0556] Use Graphpad Prism to analyze the data.
[0557] A 待测 : Absorbance of the sample to be tested
[0558] A 阳性参照 : TNFα well absorbance only;
[0559] A 阴性参照 : Absorbance of culture medium wells only;
[0560] IC of the compound 50 The value is calculated using log(inhibitor) vs. response -- Variable slope (4-parameter logical model) in GraphPad Prism.
[0561] The inhibition of TNFα-induced NF-κB activation by the disclosed compound was determined by the above experiments.
[0562] Conclusion: The compounds disclosed in this study have a strong inhibitory effect on TNFα-induced NF-κB activation.
[0563] Test Example 3. Inhibition of TNFα-induced cytotoxicity
[0564] 1. Experimental Materials
[0565] 2. Experimental Procedure
[0566] The in vitro inhibition of TNFα-induced cytotoxicity was tested using CellTiter-Glo (CTG) chemiluminescence assay. The initial concentration of the test compound for inhibiting TNFα-induced cytotoxicity was 10,000 nM, diluted 5-fold, for a total of 9 concentrations, and tested in replicates.
[0567] Prepare and dilute TNFα to its working concentration of 200 pM using complete culture medium (MEM + 10% fetal bovine serum + 1% P / S). Dilute the test compound and positive control to their working concentrations of 40 pM using complete culture medium, starting at 40 μM and serially diluting 5-fold for a total of 9 concentrations. Mix equal volumes of TNFα and the drug and incubate the mixture at 37°C for 1 hour. Centrifuge L929 cells and resuspend them in complete culture medium containing 2 μg / ml actinomycin. Seed 1000 cells per well in 20 μl of the mixture into 384-well white cell culture plates. Add 20 μl of the pre-incubated TNFα and drug mixture to the cells. After a brief centrifugation, incubate the plate at 37°C for 20 hours. After incubation, remove the plate and add 20 μl of CTG reagent to the cells. After a brief centrifugation, incubate the microplate at room temperature for 20 minutes. Use the microplate after a brief centrifugation. The i3x multi-functional microplate reader reads and records the luminescence intensity.
[0568] Analyze the data using Graphpad Prism. % Inhibition rate = [(RFU 待测 –RFU 阴性参照 ) / (RFU 阳性参照 –RFU 阴性参照 )]x100
[0569] RFU 待测 : The luminescence intensity of the sample to be tested;
[0570] RFU 阳性参照 : Light intensity only in the culture medium;
[0571] RFU 阴性参照 TNFα luminescence intensity only
[0572] IC of the compound 50 The value is calculated using log(inhibitor) vs. response -- Variable slope (4-parameter logical model) in GraphPad Prism.
[0573] The inhibition of TNFα-induced cytotoxicity by the disclosed compound was determined through the experiments described above.
[0574] Conclusion: The compound disclosed in this study has a strong inhibitory effect on TNFα-induced cytotoxicity.
[0575] Test Example 4: Pharmacokinetic Study in Mice
[0576] After the compound was prepared into a clear solution of appropriate concentration using 5% DMSO, 5% Solutol, and 90% water, male ICR mice (Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) (3 mice / compound) were administered the solution intravenously and by gavage. Plasma samples were collected at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration. Plasma concentrations were determined using LC-MS / MS, and non-compartmental analysis was performed using Phoenix WinNonlin to estimate pharmacokinetic parameters.
[0577] Table 1. Pharmacokinetic parameters of the disclosed compounds in ICR mice. Note: Administer by gavage (ig); or intravenously (iv).
[0578] Conclusion: The compound disclosed herein exhibits good pharmacokinetic absorption activity in mice.
[0579] Test Example 5. Inhibition of IL8 release from hPBMCs stimulated by TNFα
[0580] 1. Experimental Materials
[0581] 2. Experimental Methods
[0582] 1) Sample loading system for culture plate: 100 μL PBMC + 50 μL compound + 50 μL TNFα
[0583] 2) Resuscitate PBMCs, clean them once according to the procedure, filter them through a 40μm cell sieve, and count them using AOPI.
[0584] 3) Add 1E5 / well to a 96-well U plate and incubate for 4 hours in a cell culture incubator.
[0585] 4) Prepare compounds:
[0586] a. Take each compound that has been aliquoted and stored at -80℃.
[0587] b. Sample dilution table: Dilute the compound with culture medium (1:1000) to prepare a 10 μM stock solution;
[0588] 5) Mix the serially diluted compound (450 μL) with an equal volume of 2 ng / ml TNFa (450 μL) in a V-plate. Incubate at 37°C for 1 hour.
[0589] 6) Add 100 μL of the incubated mixture (compound + TNFa) to each well of the PBMC, mix well, and incubate in a cell culture incubator for 18 hours.
[0590] 7) Centrifuge at 1500 rpm for 10 min. Collect 80 μL of the supernatant, store at -80℃, and dilute 1:5 to detect IL-8.
[0591] 8) Centrifuge at 1800g for 10 min. Collect 80 μL of the supernatant and store at -80℃ for subsequent cytokine detection.
[0592] 9) Detect the extracted supernatant using an IL-8 factor detection kit. Read the absorbance.
[0593] The absorbance data were processed and analyzed using GraphPad Prism software to determine the IC50 of the compounds. 50 The value was calculated using the log(inhibitor) vs. response -- Variable slope (4-parameter logistic model) method in GraphPad Prism. The measured IC... 50 The values are shown in Table 2.
[0594] Table 2 shows the inhibitory effect of the disclosed compounds on IL8 release from TNFα-stimulated hPBMC cells.
[0595] Conclusion: The compound disclosed in this study has a strong inhibitory effect on the release of IL8 from TNFα-stimulated hPBMC cells.
[0596] Test Example 6: Pharmacokinetic Study in Rats
[0597] After the compound was prepared into a clear solution of appropriate concentration using 5% DMSO, 5% Solutol, and 90% water, male SD rats (Zhejiang Vital River Laboratory Animal Technology Co., Ltd.) (3 rats / compound) were administered the solution intravenously and by gavage. Plasma samples were collected at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration. Plasma concentrations were determined using LC-MS / MS, and non-compartmental analysis was performed using Phoenix WinNonlin to estimate pharmacokinetic parameters.
[0598] Table 3. Pharmacokinetic parameters of the disclosed compounds in SD rats. Note: Administer by gavage (ig); or intravenously (iv).
[0599] Conclusion: The compound disclosed herein exhibits good pharmacokinetic properties in rats.
[0600] Test Example 7: Pharmacokinetic Study in Dogs
[0601] The compound was prepared into a clear solution of appropriate concentration using 5% DMSO, 5% Solutol, and 90% water, and then administered intravenously to male Beagle dogs (Beijing Mars Biotechnology Co., Ltd.) (2 dogs / compound). Plasma samples were collected at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, and 24 hours after administration. Plasma concentrations were determined using LC-MS / MS, and non-compartmental analysis was performed using Phoenix WinNonlin to estimate pharmacokinetic parameters.
[0602] Table 4. Pharmacokinetic parameters of the disclosed compounds in Beagle dogs. Note: Administered intravenously (iv).
[0603] Conclusion: The compound disclosed herein exhibits good pharmacokinetic properties in dogs.
[0604] Test Example 8: Pharmacokinetic Study in Cynomolgus Monkeys
[0605] After preparing a clear solution of the compound to an appropriate concentration using 5% DMSO, 5% Solutol, and 90% water, male cynomolgus monkeys (Suzhou Xishan Zhongke Experimental Animal Co., Ltd.) (2 monkeys / compound) were administered intravenously. Plasma samples were collected at 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration. Plasma concentrations were determined using LC-MS / MS, and non-compartmental analysis was performed using Phoenix WinNonlin to estimate pharmacokinetic parameters.
[0606] Table 5. Pharmacokinetic parameters of the disclosed compounds in cynomolgus monkeys. Note: Administered intravenously (iv).
[0607] Conclusion: The compound disclosed herein exhibits good pharmacokinetic properties in cynomolgus monkeys.
Claims
The compound represented by formula (I-1), its stereoisomers, or its pharmaceutically acceptable salts, in, T x Selected from N, CH and C; T y Selected from N, CH and C; T is selected from N and C; When T is selected from N Selected from When T is selected from C Selected from T4 is selected from N and C(R2); T5 is selected from N and C(R3); T6 is selected from N and C(R4); T7 is selected from N and C(R5); And at most two of T4, T5, T6, and T7 can be selected from N simultaneously; T8 is selected from N and C(R) 10 ); T9 is selected from N and C (R9); Furthermore, at least one of T8 and T9 is selected from N; X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )2C(R b )2-、-C(R b )=C(R b )- and -C(R b )2-N(R a )-; Alternatively, when X1 is selected from -C(R) b )2-N(R a When )-, where R a With one of the R b They connect together to form a 4-6 membered heterocyclic alkyl group; X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-; Z is selected from -C(R) a )2- and -C(R b )2-; L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups; Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Ring B is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl, the C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl groups may be optionally replaced by R6, R7, or R8; Ring C is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Selected from when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1- 6-alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1- 6-alkylNH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5- 10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R; when Selected from R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10-membered heterocyclic alkenyl, wherein R1 is optionally substituted with one or more R; R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1- 6-alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3- 10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R; Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1- 6-alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R; R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1- 6-alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R 10 Selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, R8 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Or, R7 and R 10 Connected together, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Or, R 10 Connected together with R2, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's; R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's; Alternatively, R9 with the substituent R on X2 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R; Or, two Rs a Connected together, forming a C 4-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 4-7 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, when T is selected from N, R5 and the substituent R on X2 b They are linked together to form a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by one or more R; Alternatively, when T is selected from C, R5 is linked with X2 to form a 6-membered heteroaryl group, which may be optionally replaced by one or more R groups; Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Or, R 10 With the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1- 6-alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution; n is selected from 0, 1, 2 or 3. The compound according to claim 1, its stereoisomers, or pharmaceutically acceptable salts thereof, selected from the compounds of formula (I) or formula (II), their stereoisomers, or pharmaceutically acceptable salts thereof, in, T x Selected from N, CH and C; T y Selected from N, CH and C; T is selected from N and C; When T is selected from N Selected from When T is selected from C Selected from T4 is selected from N and C(R2); T5 is selected from N and C(R3); T6 is selected from N and C(R4); T7 is selected from N and C(R5); And at most two of T4, T5, T6, and T7 can be selected from N simultaneously; X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )2C(R b )2-、-C(R b )=C(R b )- and -C(R b )2-N(R a )-; Alternatively, when X1 is selected from -C(R) b )2-N(R a When )-, where R a With one of the R b They connect together to form a 4-6 membered heterocyclic alkyl group; X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-; Z is selected from -C(R) a )2- and -C(R b )2-; L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups; Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Ring B is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl, the C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 membered heteroaryl groups may be optionally replaced by R6, R7, or R8; Ring C is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Selected from when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1- 6-alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1- 6-alkylNH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5- 10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R; when Selected from R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10-membered heterocyclic alkenyl, wherein R1 is optionally substituted with one or more R; R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1- 6-alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3- 10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R; Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1- 6-alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R; R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1- 6-alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R 10 Selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, R8 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Or, R7 and R 10 Connected together, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Or, R 10 Connected together with R2, forming a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's; R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's; Alternatively, R9 with the substituent R on X2 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R; Or, two Rs a Connected together, forming a C 4-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 4-7 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, when T is selected from N, R5 and the substituent R on X2 b They are linked together to form a 5-6 membered heteroaryl group, wherein the 5-6 membered heteroaryl group is optionally substituted by one or more R; Alternatively, when T is selected from C, R5 is linked with X2 to form a 6-membered heteroaryl group, which may be optionally replaced by one or more R groups; Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Or, R 10 With the substituent R on Z a Connected together, forming a C 3-7 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-7 Cycloalkyl or 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1- 6-alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution; n is selected from 0, 1, 2 or 3. The compound according to claim 2, its stereoisomers, or pharmaceutically acceptable salts thereof, selected from the compounds of formula (IA), (IB), (II-A), or (II-B), their stereoisomers, or pharmaceutically acceptable salts thereof, in, T1 is selected from N and C(R6); T2 is selected from N and C (R7); T3 is selected from N and C(R8); T4 is selected from N and C(R2); T5 is selected from N and C(R3); T6 is selected from N and C(R4); T7 is selected from N and C(R5); And at most two of T4, T5, T6, and T7 can be selected from N simultaneously; X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )=C(R b )- and -C(R b )2C(R b )2-; X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-; Z is selected from -C(R) a )2- and -C(R b )2-; L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups; Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Selected from when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R; when Selected from When R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10-membered heterocyclic alkenyl, wherein R1 is optionally substituted with one or more R; R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1- 6-alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3- 10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R; Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1- 6-alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R; R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1- 6-alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's; R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's; Alternatively, R9 and the substituent R on X1 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R; Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, the two substituents R on Z a Connected together, forming a C 3-10 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1-6 Alkyl)3, C 1-6 Alkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution; n is selected from 0, 1, 2 or 3. The compound according to claim 3, its stereoisomers, or pharmaceutically acceptable salts thereof, selected from compounds of formula (I-A1), (I-A2), (II-A1), or (II-A2) or their pharmaceutically acceptable salts, stereoisomers, or pharmaceutically acceptable salts thereof, is further specified. in, T1 is selected from N and C(R6); T2 is selected from N and C (R7); T3 is selected from N and C(R8); T4 is selected from N and C(R2); T5 is selected from N and C(R3); T6 is selected from N and C(R4); T7 is selected from N and C(R5); And at most two of T4, T5, T6, and T7 can be selected from N simultaneously; X1 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2-、-C(R b )=C(R b )- and -C(R b )2C(R b )2-; X2 is selected from empty, -O-, -S-, -N(R) a )-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)2-, -C(R b )2- and -C(R b )2C(R b )2-; Z is selected from -C(R) a )2- and -C(R b )2-; L1 is selected from empty, -O-, -S-, -N(R) a )-、C 2-6 Olefins, C 2-6 Alkynes, C 1-6 Alkylene, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 4-10 heteroaryl groups; Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Selected from when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R; when Selected from When R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2- and 5-10-membered heterocyclic alkenyl-CH2-, wherein R1 is optionally substituted with one or more R; R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1- 6-alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3- 10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R; Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R3 and R4 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R4 and R5 can be connected together to form a C. 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1- 6-alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R; R9 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1- 6-alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl and 3-10 membered heterocycloalkyl, wherein C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 3-10 Cycloalkyl or 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, R6 and R1 can be connected together to form a C 5-7 Cycloalkyl or 5-10 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's; R b The components are independently selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl and 5-10 heteroaryl, the R b It can be replaced by one or more R's; Alternatively, R9 and the substituent R on X1 a They are linked together to form a 4-10 membered heterocyclic alkyl group, wherein the 4-10 membered heterocyclic alkyl group is optionally substituted with one or more R; Alternatively, R9 with the substituent R on Z a Connected together, forming a C 3-10 Cycloalkyl or 3-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 3-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; Alternatively, the two substituents R on Z a Connected together, forming a C 3-10 Cycloalkyl or 4-10 membered heterocycloalkyl, wherein C 3-10 Cycloalkyl and 4-10 membered heterocyclic alkyl groups may optionally be substituted with one or more R; R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1-6 Alkyl)3, C 1-6 Alkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution; n is selected from 0, 1, 2 or 3. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein, R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1-3 Alkyl)3, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-6 Cycloalkyl, 3-6 membered heterocycloalkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-6 Cycloalkyl-C(=O)-, 3-6 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10-membered heterocyclic alkenyl-C(=O)-, phenyl-C(=O)-, and 5-6-membered heteroaryl-C(=O)-, wherein R is optionally converted by one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino or (C 1-3 Alkyl)2-amino substitution; Preferably, R is selected from D, F, Cl, Br, I, OH, NH2, CN, Si(CH3)3, methyl, ethyl, propyl, isopropyl, CD3, The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1- 3alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)(=NH)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 1-3 Alkyl-NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-10 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3- 10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R; when Selected from When R1 is selected from C 1-3 Alkyl, C 3-6 Cycloalkyl, 4-6 membered heterocyclic alkyl, C 5-6 Cycloalkenyl, 5-6 membered heterocyclic alkenyl, C 3-6 Cycloalkyl-CH2-, 4-6 membered heterocyclic alkyl-CH2-, C 5-6 Cycloalkenyl-CH2- and 5-6 membered heterocyclic alkenyl-CH2-; preferably, when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Methyl, ethyl, isopropyl, R1 may be replaced by one or more R; Preferably, when Selected from When, R1 is selected Preferably, when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Methyl, ethyl, isopropyl, CD3, CF3 Preferably, when Selected from When, R1 is selected The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-3 Alkyl, C 2- 3-olefin, C 2-3 alkynyl group, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 1-3 Alkyl-C(=O)-, C 1-3 Alkyl-S(=O)-, C 1-3 Alkyl-S(=O)2-, C 1-3 Alkyl-OC(=O)-, C 1-3 Alkyl-OS(=O)-, C 1-3 Alkyl-OS(=O)2-, C 1-3 Alkyl-C(=O)-O-, C 1-3 Alkyl-S(=O)-O-, C 1-3 Alkyl-S(=O)2-O-, C 1-3 Alkyl-NH-C(=O)-, C 1-3 Alkyl-NH-S(=O)-, C 1-3 Alkyl-NH-S(=O)2-, C 1-3 Alkyl-C(=O)-NH-, C 1-3 Alkyl-S(=O)-NH-, C 1-3 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, phenyl, 5-6 membered heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10-membered heterocyclic alkenyl-O-, phenyl-O-, 5-6-membered heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5- 10 Cycloalkenyl-S-, 5-10-membered heterocyclic alkenyl-S-, phenyl-S-, 5-6-membered heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, phenyl-NH-, 5-6 membered heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10-membered heterocyclic alkenyl-CH2-, phenyl-CH2-, 5-6-membered heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more Rs; Preferably, R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, etc. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R a Selected from H, C 1-6 Deuterated alkyl groups, and C 1-3 Alkyl, the C 1-3 Alkyl groups may optionally be substituted with one or more R groups; Preferably, R a Selected from H, deuterated methyl, methyl, ethyl, propyl and isopropyl. The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R b Selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 alkylthio and C 1- 3-Alkylamino, wherein R b It can be replaced by one or more R's; Preferably, R b Selected from H, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, methyl, ethyl, propyl and isopropyl. According to claim 8 or 9, the compound, its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein, -X1-X2- Selected from The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, Cycle A is selected from furanyl, pyrrolyl, thiophenyl, pyrazolyl, imidazoleyl, oxazolyl, pyridyl, pyranoneyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, 2,3-dihydrofuran[3,2-b]pyridyl, 6,7-dihydro-5H-cyclopentan[b]pyridyl, 1H-pyrazolo[3,4-b]pyridyl, 3H-imidazo[4,5-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, 1,2,3,4-tetrahydro-1,8-naphthylpyridyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]ox Zinyl, 3,4-dihydro-2H-pyrazino[2,3-b][1,4]oxazinyl, pyrazolo[1,5-a]pyrimidinyl, pyrrolo[2,1-f][1,2,4]triazinyl, 3H-[1,2,3]triazolo[4,5-b]pyridinyl, thiazo[5,4-b]pyridinyl, pyrrolo[1,2-a][1,3,5]triazinyl, 7H-pyrrolo[2,3-c]pyridazinyl, 1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one, 3,4-dihydro-2H-pyrano[3,2-b]pyridinyl, azacyclobutyl, pyrrolidinyl, 2,4,5 ,6-Tetrahydropyrrolo[3,4-c]pyrazolyl, spiro[3,3]heptyl, cyclopentyl, bicyclo[3,1,0]hexyl, 5a,6,7,7a-tetrahydrocyclobutane[4,5]furano[3,2-b]pyridyl, 5a,7,8,8a-tetrahydro-6H-cyclopentane[4,5]furano[3,2-b]pyridyl, 5a,6a-dihydro-6H-cyclopropane[4,5]furano[3,2-b]pyridyl, 5,5a,6,7,8,8a-hexahydropentene[1,2-b]pyridyl, 4b,5,5a,6-tetrahydrocyclopropane[3,4]cyclopentane[1,2-b]pyridyl, 5a,6,7,7a-tetrahydro-5H-cyclobutane[4,5]cyclo Pentyl[1,2-b]pyridyl, 6a,7,8,8a-tetrahydro-6H-cyclobutane[4,5]pyrano[3,2-b]pyridyl, 2',3'-dihydrospiro[azacyclobutane-2,4'-pyrano[3,2-b]pyridyl]yl, 2',3'-dihydrospiro[aziridin-2,4'-pyrano[3,2-b]pyridyl]yl, 7,8-dihydro-6H-pyrano[2,3-b]pyrazinyl, 3,4-dihydro-2H-2,4-methanepyrano[3,2-b]pyridyl, 6,7-dihydro-5H-cyclopentyl[b]pyrazinyl, 6,7-dihydro-5H-cyclopentyl[c]pyridazinyl, phenyl, thiazolyl, isothiazolyl, isoxazolyl, 3-azabicyclo[4.2].[0] Octane-1(6),2,4-trienyl, 6,7-dihydro-5H-cyclopentan[c]pyridyl, 1,3-dihydrofuran[3,4-c]pyridyl, 2,3-dihydrofuran[2,3-c]pyridyl, nitropyridyl, nitropyridazinyl, nitropyrimidinyl, and nitropyrazinyl. According to claim 6 or 11, the stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein, Structural unit Selected from The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, Ring L1 is selected from empty, According to claim 12 or 13, the compound, its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein, Structural unit Selected from The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R2 and R3 are connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Preferably, R2 and R3 are connected together to form Alternatively, R3 and R4 can be connected together to form... Alternatively, R4 and R5 can be connected together to form... The compound, its stereoisomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1-5, wherein, R6 and R1 are connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; Alternatively, R9 and the substituent R on X1 a They are linked together to form a 4-7 membered heterocyclic alkyl group, wherein the 4-7 membered heterocyclic alkyl group is optionally substituted with one or more R; Preferably, R6 is connected to R1 to form oxetyl, oxetylhexyl, azityl, azitylhexyl, oxetylheptyl or azitylheptyl, wherein the oxetyl, oxetyl, azityl, azitylhexyl, oxetylheptyl and azitylheptyl may optionally be substituted by one or more R. Alternatively, R9 and the substituent R on X1 a They are linked together to form azircyclobutyl, azircyclopentyl, azircyclohexyl, or azircycloheptyl, wherein the azircyclobutyl, azircyclopentyl, azircyclohexyl, and azircycloheptyl may optionally be substituted with one or more R. According to claims 1-16, the compounds, their stereoisomers, or pharmaceutically acceptable salts thereof, selected from compounds of formula (III-A1) or (III-A2), their pharmaceutically acceptable salts, their stereoisomers, or pharmaceutically acceptable salts thereof, in, q is selected from 0, 1, 2 or 3, R1, ring A, L1, R6, R 10 R a T4, T5, T6, T7, and n are as defined in claims 1-16. According to claims 1-16, the compounds, their stereoisomers, or pharmaceutically acceptable salts thereof, wherein the compounds are selected from those of formula (II-A3), (II-A4), or (II-A5), or their pharmaceutically acceptable salts, their stereoisomers, or their pharmaceutically acceptable salts. in, Ring A is selected from C 3-15 Cycloalkyl, 3-15 membered heterocycloalkyl, C 5-15 Cycloalkenyl, 5-15 membered heterocyclic alkenyl, C 6-15 Aryl and 5-15 quinone heteroaryl groups; Selected from when Selected from When R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 1-6 Alkyl NH-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, C 3-10 Cycloalkyl-O-CH2-, 3-10 membered heterocyclic alkyl-O-CH2-, C 5-10 Cycloalkenyl-O-CH2-, 5-10 membered heterocyclic alkenyl-O-CH2-, C 6-10 aryl-O-CH2-, 5-10 heteroaryl-O-CH2-, C 3-10 Cycloalkyl-S-CH2-, 3-10 membered heterocyclic alkyl-S-CH2-, C 5-10 Cycloalkenyl-S-CH2-, 5-10 membered heterocyclic alkenyl-S-CH2-, C 6-10 aryl-S-CH2-, 5-10 heteroaryl-S-CH2-, C 3-10 Cycloalkyl-NH-CH2-, 3-10 membered heterocyclic alkyl-NH-CH2-, C 5-10 Cycloalkenyl-NH-CH2-, 5-10 membered heterocyclic alkenyl-NH-CH2-, C 6-10 aryl-NH-CH2- and 5-10 heteroaryl-NH-CH2-, wherein R1 is optionally substituted by one or more R; when Selected from When R1 is selected from C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2- and 5-10-membered heterocyclic alkenyl-CH2-, wherein R1 is optionally substituted with one or more R; R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1- 6-alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3- 10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R2, R3, R4, and R5 are optionally substituted by one or more R; Alternatively, R2 and R3 can be connected together to form a C 5-7 Cycloalkyl or 5-7 membered heterocycloalkyl, wherein C 5-7 Cycloalkyl and 5-7 membered heterocycloalkyl groups may optionally be substituted with one or more R; R6, R7, and R8 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, and C, respectively. 1- 6-alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-O-, 3-10 membered heterocyclic alkyl-O-, C 5-10 Cycloalkenyl-O-, 5-10 membered heterocyclic alkenyl-O-, C 6-10 Aryl-O-, 5-10 heteroaryl-O-, C 3-10 Cycloalkyl-S-, 3-10 membered heterocycloalkyl-S-, C 5-10 Cycloalkenyl-S-, 5-10 membered heterocyclic alkenyl-S-, C 6-10 Aryl-S-, 5-10 heteroaryl-S-, C 3-10 Cycloalkyl-NH-, 3-10 membered heterocyclic alkyl-NH-, C 5-10 Cycloalkenyl-NH-, 5-10 membered heterocyclic alkenyl-NH-, C 6-10 aryl-NH-, 5-10 heteroaryl-NH-, C 3-10 Cycloalkyl-CH2-, 3-10 membered heterocyclic alkyl-CH2-, C 5-10 Cycloalkenyl-CH2-, 5-10 membered heterocyclic alkenyl-CH2-, C 6-10 aryl-CH2-, 5-10 heteroaryl-CH2-, wherein R6, R7, and R8 are optionally substituted by one or more R; R a Selected from H, C 1-6 Deuterated alkyl, C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl and 5-10 membered heterocyclic alkenyl, wherein R a It can be replaced by one or more R's; R is selected from D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Si(C 1-6 Alkyl)3, C 1-6 Alkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkyl-C(=O)-, C 1-6 Alkyl-S(=O)-, C 1-6 Alkyl-S(=O)2-, C 1-6 Alkyl-OC(=O)-, C 1-6 Alkyl-OS(=O)-, C 1-6 Alkyl-OS(=O)2-, C 1-6 Alkyl-C(=O)-O-, C 1-6 Alkyl-S(=O)-O-, C 1-6 Alkyl-S(=O)(=NH)-O-, C 1-6 Alkyl-S(=O)2-O-, C 1-6 Alkyl-NH-C(=O)-, C 1-6 Alkyl-NH-S(=O)-, C 1-6 Alkyl-NH-S(=O)2-, C 1-6 Alkyl-C(=O)-NH-, C 1-6 Alkyl-S(=O)-NH-, C 1-6 Alkyl-S(=O)2-NH-, C 3-10 Cycloalkyl, 3-10 membered heterocyclic alkyl, C 5-10 Cycloalkenyl, 5-10 membered heterocyclic alkenyl, C 6-10 Aryl, 5-10 heteroaryl, C 3-10 Cycloalkyl-C(=O)-, 3-10 membered heterocycloalkyl-C(=O)-, C 5-10 Cycloalkenyl-C(=O)-, 5-10 membered heterocyclic alkenyl-C(=O)-, C 6-10 aryl-C(=O)- and 5-10 heteroaryl-C(=O)-, wherein the R is optionally coated with one or more D, F, Cl, Br, I, OH, NH2, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or (C 1-6 Alkyl)2-amino substitution; n is selected from 0, 1, 2, or 3; Preferably, Selected from Preferably, R a The compound is selected from H, deuterated methyl, methyl, ethyl, propyl and isopropyl, wherein the deuterated methyl includes -CH=D, -CHD2, and -CD3; Or preferably, R2 and R3 are connected together to form Preferably, R2, R3, R4, and R5 are independently selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, etc. Preferably, R1 is selected from H, D, F, Cl, Br, I, OH, NH2, CN, C(=O)OH, C(=O)NH2, Methyl, ethyl, isopropyl, The R1 may be optionally substituted with one or more Rs; preferably, R is selected from D, F, Cl, Br, I, OH, NH2, CN, Si(CH3)3, methyl, ethyl, propyl, isopropyl, CD3, The compound according to any one of claims 1-18, its stereoisomer, or a pharmaceutically acceptable salt thereof, is selected from any of the following compounds. A pharmaceutical composition comprising the compound of any one of claims 1-19, its stereoisomer, or a pharmaceutically acceptable salt thereof. Use of the compound of any one of claims 1-19, its stereoisomer or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 20 in the preparation of a TNFα inhibitor medicament. Use of the compound of any one of claims 1-19, its stereoisomers or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 20 in the preparation of a medicament for treating TNFα-related diseases; optionally, the TNFα-related diseases are selected from anti-inflammatory or autoimmune disorders, neurological or neurodegenerative disorders, pain or nociceptive disorders, cardiovascular disorders, metabolic disorders, eye disorders or oncological disorders; preferably, the TNFα-related diseases are selected from rheumatoid arthritis. Inflammation, psoriatic arthritis, inflammatory bowel disease, psoriasis, Crohn's disease, ulcerative colitis, psoriasis, spondyloarthritis, plaque psoriasis, septic shock, ankylosing spondylitis, juvenile idiopathic arthritis, hidradenitis suppurativa, uveitis, systemic lupus erythematosus, axial spondyloarthritis, polymyositis, pemphigus, multiple sclerosis, neuromyelitis optica, primary cholangitis, autoimmune hepatitis, lupus nephritis, pulmonary hemorrhage-nephritis syndrome, autoimmune oophoritis or autoimmune orchitis.
